

Bibliography of Publications

1998–2004

Bibliography

Introduction

Welcome to the National Institute for Clinical Excellence's bibliography.

The objective of this project is to identify, in the broadest sense, the scientific and technical literature relating to the work of the Institute and to help develop a greater understanding of our current work programmes. In particular, to we expect the bibliography will:

- assist NICE staff, members of the committees and NCCs when writing about the Institute's work.
- assist others in the global scientific, technical and clinical fields who wish to learn, or write, about the Institute's work.
- record NICE's contributions to clinical standard setting.
- mark five years of the Institute as, amongst other things, an academic organisation.

This bibliography is therefore an attempt to capture the literature, relating to NICE, published in peer reviewed professional journals.

Sources

The articles included comprise

- original articles
- signed and unsigned editorials, commentaries etc
- correspondence in respect of original articles and editorials

- news items selected from the British Medical Journal and the Lancet
- material published by the Institute.


The bibliography includes some but, perhaps not all, relevant "grey" literature such as proceedings of parliamentary select committees, government reports, as well as a small number of other articles published in non-peer reviewed journals that offer significant/important/useful insights into the work of the Institute. This literature has mainly been identified from memory. It generally excludes articles published in medical and pharmaceutical magazines (for example, Scrip) and newspapers (for example, Pulse), non-peer reviewed journals, and the lay media.

Whilst we have endeavoured to search widely, the bibliography is a working project to be maintained and updated. It has been constructed from a scrutiny of bibliographic databases and hand searching of indexes. Not all the "news" items in the BMJ or Lancet have been included. Those excluded carried no particular message and merely "reported" the recent publication of an appraisal or guideline. Those that have been incorporated are those with "added value" in the form of comments from critics or supporters.

Finally, there is some published material in legal, philosophical and political science journals but we cannot be sure that they have all been captured.

The number of publications by NICE, itself, has risen exponentially since the Institute's formation. To date (up to and including Q1 2004) NICE has published 175 items of guidance and reports.

1998



There are likely to be further publications about NICE published in 2003, which have not yet been indexed in bibliographic databases

* Q1 data only

The bibliography will be updated annually at the beginning of April. If you find a citation has not been included, please email Karin Dearness, Information Specialist at karin.dearness@nice.nhs.uk

Karin Dearness, Jackie Larsen & Mike Rawlins
April 2004

Anonymous (1998) Industry seeks role in UK clinical institute. *SCRIP World Pharmaceutical News* (2305): 4.

Anonymous (1998) The man from NICE. *British Medical Journal* 317 (7171): 1476.

Anonymous (1998) Tighter controls on UK NHS & industry. *SCRIP World Pharmaceutical News* (2392): 6.

Burnett A, Winyard G (1998) Clinical audit at the heart of clinical effectiveness. *Journal of Quality in Clinical Practice* 18 (1): 3–19.

Day P, Klein R, Miller F (1998) *Hurdles and levers : a comparative US-UK study of guidelines*. London: Nuffield Trust.

Dean M (1998) UK ministers seek NICE new health efficiencies: National Institute for Clinical Effectiveness. *Lancet* 352 (9140): 1607.

Department of Health (1998) *A first class service: quality in the new NHS*. London: Stationary Office 86p.

Kenny C (1998) Nice idea, shame about the pace. *Nursing Times* 94 (1): 15.

Kerr D (1998) NHS White Paper: a NICE idea. *Journal of the Royal College of Physicians of London* 32 (1): 5.

Loveday R (1998) Not so NICE for most researchers (National Institute of Clinical Effectiveness). *Nursing Standard* 12 (18): 14.

Mason J (1998) *NICEly does it : economic analysis within evidence-based practice guidelines*. York: University of York. Centre for Health Economics.

Millson D, Chapman S (1998) Medicines management: NICE (National Institute for Clinical Excellence) but not easy. *Health Service Journal* 108 (5625): 35.

Simister K, Jackson C (1998) Informing the effective introduction of new drugs into the National Health Service. *Pharmaceutical Journal* 261 (7003): 90–92.

Song F, Glenny A (1998) Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomised controlled trials. *Health Technology Assessment* 2 (7): 1–110.

Sutton A, Abrams K, Jones D et al (1998) Systematic reviews of trials and other studies. *Health Technology Assessment* 2 (19): 1–276.

Veldhuis M, Wigersma L, Okkes I (1998) Deliberate departures from good general practice: a study of motives among Dutch general practitioners. *British Journal of General Practice* 48 (437): 1833–1836.

Wilson P (1998) Delivering a first class service: The role of NICE. *Audit Trends* 6 (3): 81–82.

1999

Anonymous (1999) A nasty start for NICE. *Lancet* 354 (9187): 1313.

Anonymous (1999) NICE to increase regulatory burden? *SCRIP World Pharmaceutical News* (2411): 2.

Anonymous (1999) No flexibility in UK NICE advice. *SCRIP World Pharmaceutical News* (2439): 6.

Anonymous (1999) Ten million pounds sterling budget for NICE. *SCRIP World Pharmaceutical News* (2430): 4.

Anonymous (1999) UK Viagra ruling threatens NICE advice. *SCRIP World Pharmaceutical News* (2442/43): 2.

Anonymous (1999) Zanamivir and the NICE – The Relenza story unfolds. *International Journal of Pharmaceutical Medicine* 13 (6): 307.

Anonymous (1999) Zanamivir for influenza. *Drug & Therapeutics Bulletin* 37 (11): 81–84.

Burke K (1999) NICE and easy. National Institute for Clinical Excellence. *Nursing Standard* 13 (30): 13.

Burke K (1999) Nice 'n' easy. *Nursing Standard* 13 (48): 12.

Campbell B, Peveler R (1999) DEC methods for appraising new drugs. Are a foundation for the nice appraisal committee. *British Medical Journal* 319 (7215): 1005–1007.

Cardy P (1999) NICE or NASTY for MS? *The Health Summary* 16 (10): 6–7.

Coulter A (1999) NICE and CHI; reducing variations and raising standards. In: Appleby J, Harrison A, editors. *Health care UK 1999/2000: the King's Fund review of health policy*. London: King's Fund Publishing, p 119–128.

Culshaw H (1999) Secondment to NICE: An achievement. *British Journal of Occupational Therapy* 62 (11): 524.

Dewar S (1999) Viagra: the political management of rationing. In: Appleby J, Harrison A, editors. *Health care UK 1999/2000: the King's Fund review of health policy*. London: King's Fund Publishing, p 139–151.

Earl-Slater A (1999) Clinical guidelines. Nice work: spell it out for me. *Health Service Journal* 109 (5679): 24–25.

- Ellis S (1999) Some unanswered questions about NICE. *Journal of the Royal Society of Medicine* 92 (10): 538–539.
- Fox S (1999) Flu therapeutic nixed in the U.K. *Genetic Engineering News* 19 (19): 24–29.
- Freemantle N, Mason J (1999) DEC methods for appraising new drugs: authors reply. *British Medical Journal* 319 (7215): 1005.
- Freemantle N, Mason J (1999) Not playing with a full DEC: Why development and evaluation committee methods for appraising new drugs may be inadequate. *British Medical Journal* 318 (7196): 1480–1482.
- Gilbody S (1999) NICE work? Potential and problems for psychiatry in the new National Health Service. *Psychiatric Bulletin* 23 (9): 513–516.
- Glenny A, Song F (1999) Antimicrobial prophylaxis in total hip replacement: a systematic review. *Health Technology Assessment* 3 (21): 1–57.
- Goodman N (1999) A NICE programme. *Lancet* 353 (9167): 1887.
- Gray J (1999) NICE prospects for best practice. National Institute for Clinical Excellence. *Nursing Standard* 13 (29): 3.
- Harman R (1999) The National Institute for Clinical Excellence. *Pharmaceutical Journal* 263 (7073): 869–876.
- Horton R (1999) NICE: a step forward in the quality of NHS care. National Institute for Clinical Excellence. National Health Service. *Lancet* 353 (9158): 1028–1029.
- James A (1999) Clinical governance and mental health: A system for change. *Clinician in Management* 8 (2): 92–100.
- Jones J (1999) Influenza drug to undergo "fast track" assessment by NICE. *British Medical Journal* 319 (7207): 400.
- Kunkler I (1999) NICE. *Journal of the Royal College of Physicians of London* 33 (5): 486.
- Legge A (1999) Nice little earner. *Nursing Times Nursing Homes* 1 (1): 7.
- Littlejohns P (1999) Clinical governance and NICE: a close relationship. *Clinical Performance & Quality Health Care* 7 (4): 152–154.
- Mahony C (1999) What is NICE. National Institute for Clinical Excellence. *Nursing Times* 95 (10): 16.
- McClarey M (1999) NICE work for nursing. Interview by Dina Leifer. *Nursing Standard* 14 (12): 17–14.
- Mitchell P (1999) Glaxo Wellcome disputes NICE's recommendation against zanamavir. *Lancet* 354: 1275.
- Munro R (1999) A nice try. *Nursing Times* 95 (33): 14–15.
- National Health Service for England and Wales (1999) National Institute for Clinical Excellence regulations. No. 260 p1–14.
- National Health Service for England and Wales (1999) The National Institute for Clinical Excellence (Establishment and Constitution) Order. No. 220.
- NHS Executive (1999) *National Institute for Clinical Excellence. initial work programme*. HSC 1999/176.NHS Executive.
- NHS Executive (1999) *Faster Access to Modern Treatment: How NICE Appraisal Will Work, a discussion paper*. Leeds: The Executive 32p.
- Packer C, Fidan D (1999) DEC methods for appraising new drugs: horizon scanning is important for emerging health technologies. *British Medical Journal* 319 (7215): 1005.
- Radford G, Rawlins M (1999) The National Institute for Clinical Excellence: the government's agenda and the College's role. *Journal of the Royal College of Physicians of London* 33 (4): 303–304.
- Rawlins M (1999) In pursuit of quality: the National Institute for Clinical Excellence. *Lancet* 353 (9158): 1079–1082.
- Renson T (1999) Sign now ... Nice next? *Primary Dental Care* 6 (4): 125.
- Robert G, Stevens A, Gabbay J (1999) 'Early warning systems' for identifying new healthcare technologies. *Health Technology Assessment* 3 (13): 1–108.
- Rosen R, Gabbay J (1999) Linking health technology assessment to practice. Interview by Abi Berger. *British Medical Journal* 319 (7220): 1292.
- Shuttleworth A (1999) NICE puts clinical governance on the agenda. *Professional Nurse* 14 (9): 605.
- Smith R (1999) NICE: a panacea for the NHS? *British Medical Journal* 318 (7187): 823–824.
- Snell N (1999) The clinical benefits of zanamivir in influenza. *International Journal of Pharmaceutical Medicine* 13 (6): 333–335.
- Stein K (1999) DEC methods for appraising new drugs: are justified. *British Medical Journal* 319 (7215): 1005.

Stevens A, Payne N, Akehurst R et al (1999) DEC methods for appraising new drugs: paper has errors and omissions. *British Medical Journal* 319 (7215): 1005.

Stevens A, Milne R, Lilford R et al (1999) Keeping pace with new technologies: systems needed to identify and evaluate them. *British Medical Journal* 319 (7220): 1291.

Tiner R (1999) Regulatory issues around NICE. *Good Clinical Practice Journal* 6 (4): 14.

Vrhovac B, Vrhovac R (1999) The drug field (world) in the year 1998. *Pharmaca* 37 (1): 1–27.

Warden J (1999) NICE to sort clinical "wheat from chaff". *British Medical Journal* 318 (7181): 416B.

Yamey G (1999) NICE to rule on influenza flu drug zanamivir. *British Medical Journal* 319 (7215): 937.

Yamey G (1999) Chairman of NICE admits that its judgements are hard to defend. *British Medical Journal* 319 (7219): 1222.

Yamey G (1999) Dobson backed NICE ruling on flu drug. *British Medical Journal* 319 (7216): 1024.

2000

Anonymous (2000) BMJ editor calls for honest and open NICE. *SCRIP World Pharmaceutical News* (2600): 2.

Anonymous (2000) Experts query benefit of NICE U-turn on flu drug. *Nursing Times* 96 (48): 7.

Anonymous (2000) MS therapy cost-effectiveness unknown. *SCRIP World Pharmaceutical News* (2568): 3.

Anonymous (2000) New UK body to choose topics for NICE. *SCRIP World Pharmaceutical News* (2599): 5.

Anonymous (2000) NICE and DoH reassure US pharma. *SCRIP World Pharmaceutical News* (2602): 6.

Anonymous (2000) NICE clears Avandia for 2nd-line use. *SCRIP World Pharmaceutical News* (2568): 2.

Anonymous (2000) NICE clears gpIIb/IIIa inhibitors. *SCRIP World Pharmaceutical News* (2580): 2.

Anonymous (2000) NICE guide on secondary MI prophylaxis. *Chemist Druggist*: 10.

Anonymous (2000) NICE issues guidance on 'super aspirins'. *Chemist Druggist*: 10.

Anonymous (2000) NICE issues guidance on hips. *British Journal of Perioperative Nursing* 10 (6): 285.

Anonymous (2000) NICE on asthma inhaler systems. *SCRIP World Pharmaceutical News* (2574): 2.

Anonymous (2000) NICE opts for transparency. *SCRIP World Pharmaceutical News* (2594): 4.

Anonymous (2000) NICE recommends wider use of methylphenidate in ADHD. *Pharmaceutical Journal* 265 (7121): 675.

Anonymous (2000) NICE response to Deloitte report. *SCRIP World Pharmaceutical News* (2561): 4.

Anonymous (2000) NICE rules on costs only when asked. *SCRIP World Pharmaceutical News* (2558): 3.

Anonymous (2000) NICE should be independent, says APG. *SCRIP World Pharmaceutical News* (2563): 2.

- Anonymous (2000) NICE to open up appraisal process. *SCRIP World Pharmaceutical News* (2602): 5.
- Anonymous (2000) NICE to recommend Relenza for limited use? *SCRIP World Pharmaceutical News* (2583): 4.
- Anonymous (2000) NICE to seek international role. *SCRIP World Pharmaceutical News* (2562): 4.
- Anonymous (2000) NICE to vet anti-smoking treatments. *Nursing Times* 96 (47): 6–29.
- Anonymous (2000) No political interference in NICE. *SCRIP World Pharmaceutical News* (2598): 3.
- Anonymous (2000) Paclitaxel should be standard therapy for ovarian cancer, says NICE. *Pharmaceutical Journal* 264 (7096): 716.
- Anonymous (2000) Poor UK funding for Alzheimer's. *SCRIP World Pharmaceutical News* (2584): 2.
- Anonymous (2000) Taurel attacks use of health outcomes. *SCRIP World Pharmaceutical News* (2555): 7.
- Anonymous (2000) UK committee calls for extra cancer funding. *SCRIP World Pharmaceutical News* (2566): 3.
- Anonymous (2000) UK to monitor uptake of NICE guidance. *SCRIP World Pharmaceutical News* (2598): 2.
- Anonymous (2000) When I use a word...nice? *British Medical Journal* 320 (7237): 750B.
- Anthony D (2000) Clinical guidelines; an increase in interest in the UK. *Clinical Effectiveness in Nursing* 4 (4): 198–204.
- Appleby J (2000) Data briefing: NICE (National Institute for Clinical Excellence). *Health Service Journal* 110 (5708): 32.
- Appleby, J, Harrison, A (editors) (2000) *Health care UK; Autumn 2000; the King's Fund review of health policy*. London: King's Fund Publishing.
- Beecham L (2000) NICE issues guidance on using coronary artery stents. *British Medical Journal* 320 (7245): 1293.
- Bell A (2000) Relenza: out in the cold? In: Appleby J, Harrison A, editors. *Health care UK Spring 2000: the King's Fund review of health policy*. London: King's Fund Publishing, p 30–32.
- Bower A (2000) Review of circulars and official publications. *Hospital Pharmacist* 7 (9): 241.
- Branas P, Jordan R, Fry-Smith A et al (2000) Treatments for fatigue in multiple sclerosis: a rapid and systematic review. *Health Technology Assessment* 4 (27): 1–61.
- Brennan A, Akehurst R (2000) Modelling in health economic evaluation. What is its place? What is its value? *Pharmacoeconomics* 17 (5): 445–459.
- Campling A (2000) The confidential enquiry into stillbirths and deaths in infancy. *Care of the Critically Ill* 16 (4): 132–133.
- Camps-Walsh G (2000) NICE: opportunity or threat? *International Journal of Medical Marketing* 1 (1): 59–65.
- Canning D (2000) Unanswered questions about NICE. *Journal of the Royal Society of Medicine* 93 (1): 54.
- Carnall D (2000) Website of the week: Competing interests. *British Medical Journal* 320 (7229): 258a.
- Charlton B (2000) The management of scientific knowledge in medicine: a change of direction with profound implications. In: Mile A, Hampton J, Hurwitz B, editors. *NICE, CHI and the NHS reforms: enabling excellence or imposing control*. Chapter 2. London: UeL Centre for Health Services Research, p 13–31.
- Chu A (2000) How nice is NICE? *CME Bulletin Dermatology* 2 (2): 39.
- Coulter A (2000) Four challenges for NHS policy-makers. In: Hill A, editor. *What's gone wrong with health care?: challenges for the new millennium*. Chapter 12. London: King's Fund Publishing, p 99–107.
- Cream J, Cayton H (2000) New drugs for Alzheimer's disease – A consumer perspective. *Cpd Bulletin Old Age Psychiatry* 2 (3): 80–82.
- Daniels N (2000) Accountability for reasonableness. *British Medical Journal* 321 (7272): 1300–1301.
- Dean M (2000) BMA and NICE under attack over family doctor's targets. British Medical Association. National Institute for Clinical Excellence. *Lancet* 356 (9245): 1909.
- Dean M (2000) Record spending on UK health, but still a long way to go. *Lancet* 356 (9248): 2165.
- Dixon J (2000) A "common sense revolution" for UK health care? The conservatives unveil their latest plans. *British Medical Journal* 321 (7253): 63–64.
- Dobbs F (2000) Treatment of venous leg ulcers. Nice study, pity about the sample size. *British Medical Journal* 320 (7232): 446–447.

Dobson R (2000) NICE issues new guidelines on Ritalin. *British Medical Journal* 321 (7269): 1100.

Dodds I (2000) NICE and the ultimate decision makers: the legal framework for prescription and reimbursement of medicines. In: Mile A, Hampton J, Hurwitz B, editors. *NICE, CHI and the NHS reforms: enabling excellence or imposing control*. Chapter 8. London: UeL Centre for Health Services Research, p 103–125.

Eaton L (2000) A dose of scepticism. *Health Service Journal* 110 (5714): 11–12.

Ferriman A (2000) Milburn to monitor implementation of NICE guidance. National Institute for Clinical Excellence. *British Medical Journal* 321 (7274): 1431.

Ferriman A (2000) NICE issues guidance for heartburn and indigestion. *British Medical Journal* 321 (7255): 197.

Fletcher P (2000) Do NICE and CHI have no interest in safety? Opinion of the book NICE, CHI and the NHS reforms. Enabling excellence or imposing control? *Adverse Drug Reactions & Toxicological Reviews* 19 (3): 167–176.

Freemantle N (2000) Valuing the effects of sildenafil in erectile dysfunction. Strong assumptions are required to generate a QALY value. *British Medical Journal* 320 (7243): 1156–1157.

Gilbert D, Walley T, New B (2000) Lifestyle medicines. *British Medical Journal* 321 (7272): 1341–1344.

Goodman N (2000) NICE and the new command structure: Some thoughts on evidence, competence and authority. *Radiography* 6 (1): 3–7.

Goodman N (2000) Personal views: rational rationing. *British Medical Journal* 321 (7272): 1356.

Goodman N (2000) Rational rationing. *British Medical Journal* 321 (7272): 1356.

Grahame-Smith D (2000) The effect of NICE and CHI on scientific and therapeutic innovation. In: Mile A, Hampton J, Hurwitz B, editors. *NICE, CHI and the NHS reforms: enabling excellence or imposing control*. Chapter 12. London: UeL Centre for Health Services Research, p 161–168.

Hampton J (2000) Evidence, guidelines, audit and cardiology: principles and problems in secondary and tertiary care. In: Mile A, Hampton J, Hurwitz B, editors. *NICE, CHI and the NHS reforms: enabling excellence or imposing control*. Chapter 5. London: UeL Centre for Health Services Research, p 65–78.

Harrison S (2000) NICE, CHI, clinical governance and health care rationing. *Radiography* 6 (1): 9–10.

Harrison S, Dowswell G (2000) The selective use by NHS management of NICE-promulgated guidelines: a new and effective tool for systematic rationing of new therapies. In: Mile A, Hampton J, Hurwitz B, editors. *NICE, CHI and the NHS reforms: enabling excellence or imposing control*. Chapter 7. London: UeL Centre for Health Services Research, p 89–101.

Hartung H (2000) NICE and drugs for multiple sclerosis. National Institute of Clinical Excellence. *Lancet* 356 (9235): 1114.

Hunter D (2000) Managing the NHS. In: Appleby J, Harrison A, editors. *Health care UK Winter 2000: the Kings Fund review of health policy*. London: King's Fund Publishing, p 69–76.

Hurwitz B (2000) A NICE winter conference. *Journal of the Royal College of Physicians of London* 34 (4): 389–390.

Hurwitz B (2000) Clinical guidelines, NICE products and legal liability? In: Mile A, Hampton J, Hurwitz B, editors. *NICE, CHI and the NHS reforms: enabling excellence or imposing control*. Chapter 11. London: UeL Centre for Health Services Research, p 153–160.

Hutton J, Maynard A (2000) A nice challenge for health economics. *Health Economics* 9 (2): 89–93.

James R (2000) The impact of NICE and CHI on cancer and diagnostic radiology services. *Radiography* 6 (2): 71–74.

James R, Vaile M, Burrell A, et al. (2000) Evidence, guidelines, audit and oncology: principles and problems in secondary and tertiary care. In: Mile A, Hampton J, Hurwitz B, editors. *NICE, CHI and the NHS reforms: enabling excellence or imposing control*. Chapter 6. London: UeL Centre for Health Services Research, p 79–88.

Jones A (2000) Health technology assessment and appraisal: Evidence-based rationing? *Journal of Biolaw & Business* 3 (2): 56–61.

Kanavos P, Trueman P, Bosilevac A (2000) Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United Kingdom. *International Journal of Technology Assessment in Health Care* 16 (4): 1179–1192.

- Karr A (2000) The comparative utilisation of resources evaluation model – A CURE for all diseases. *Pharmaceutical Journal* 265 (7119): 619–621.
- Kmietowicz Z (2000) NICE approves Taxol for ovarian cancer. *British Medical Journal* 320 (7245): 1293.
- Kmietowicz Z (2000) NICE's appraisal procedures attacked. *British Medical Journal* 321 (7267): 980.
- Kozma C (2000) Evidence-based practices and the National Institute for Clinical Excellence. *Managed Care Interface* 13 (2): 70–71.
- Leatherman S, Berwick D (2000) The NHS through American eyes. *British Medical Journal* 321 (7276): 1545–1546.
- Lister-Sharp D, McDonagh M, Khan K et al (2000) A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. *Health Technology Assessment* 4 (17): 1–113.
- Littlejohns P (2000) NICE and psychiatry. *Advances in Psychiatric Treatment* 6 (5): 321–326.
- Loughlin M (2000) 'Quality' and 'excellence': meaning versus rhetoric. In: Mile A, Hampton J, Hurwitz B, editors. *NICE, CHI and the NHS reforms: enabling excellence or imposing control*. Chapter 1. London: UeL Centre for Health Services Research, p 1–12.
- Lovatt B (2000) Relenza catches a cold – The art and science of NICE appraisal. *Good Clinical Practice Journal* 7 (1): 6–7.
- Lovatt B, Mills F (2000) The National Institute for Clinical Excellence – Controlling healthcare costs with evidence. *Good Clinical Practice Journal* 7 (8): 10–15.
- MacDonald R (2000) More drugs pass the NICE test. *British Medical Journal* 321 (7265): 853.
- Majeed A, Moser K, Maxwell R (2000) Age, sex and practice variations in the use of statins in general practice in England and Wales. *Journal of Public Health Medicine* 22 (3): 275–279.
- Mason J, Eccles M, Freemantle N, et al. (2000) A NICE start?: Economic analysis within evidence-based clinical practice guidelines. In: Smith P, editor. *Reforming markets in health care*. Chapter 10. Buckingham: Open University Press, p 211–245.
- Mauskopf J (2000) Meeting the NICE requirements: A markov model approach. *Value in Health* 3 (4): 287–293.
- McClarey M (2000) NICE: exciting developments. *Professional Nurse* 16 (2): 875.
- McDonagh M, Bachmann L, Golder S et al (2000) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina. *Health Technology Assessment* 4 (30): 1–95.
- Mead P (2000) Clinical guidelines: promoting clinical effectiveness or a professional minefield? *Journal of Advanced Nursing* 31 (1): 110–116.
- Meads C, Cummins C, Jolly K et al (2000) Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. *Health Technology Assessment* 4 (23): 1–153.
- Miles, A, Hampton, JR, and Hurwitz, BS (editors) (2000) *NICE, CHI and the NHS reforms: enabling excellence or imposing control?* London: Aesculapius Medical Press.
- Morant H (2000) NICE issues guidelines on wisdom teeth. *British Medical Journal* 320 (7239): 890A.
- Munro R (2000) Drug ruling. RCN gets nasty over NICE decision. *Nursing Times* 96 (35): 6-Sep.
- National Institute for Clinical Excellence (2000) *Annual report 1999–2000: combined annual report and accounts*. London: National Institute for Clinical Excellence.
- National Institute for Clinical Excellence (2000) *Business plan 2000–2001*. London: National Institute for Clinical Excellence 34p.
- National Institute for Clinical Excellence (2000) *Compilation: summary of guidance issued to the NHS in England and Wales*. Issue 1. London: National Institute for Clinical Excellence.
- National Institute for Clinical Excellence (2000) *Corporate plan 2000–2003*. London: National Institute for Clinical Excellence 33p.
- National Institute for Clinical Excellence (2000) *Guidance on coronary artery stents in the treatment of ischaemic heart disease*. NICE Technology Appraisal Guidance No.4. London: National Institute for Clinical Excellence.
- National Institute for Clinical Excellence (2000) *Guidance on rosiglitazone for Type 2 diabetes mellitus*. NICE Technology Appraisal Guidance No.9. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the use of zanamivir (Relenza) in the treatment of influenza. NICE Technology Appraisal Guidance No.15*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the use of ribavirin and interferon alpha for hepatitis C. NICE Technology Appraisal Guidance No.14*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the use of laparoscopic surgery for colorectal cancer. NICE Technology Appraisal Guidance No.17*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the use of taxanes for ovarian cancer. NICE Technology Appraisal Guidance No.3*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes. NICE Technology Appraisal Guidance No.12*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the selection of prostheses for primary total hip replacement. NICE Technology Appraisal Guidance No.2*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the use of liquid-based cytology for cervical screening. NICE Technology Appraisal Guidance No.5*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the removal of wisdom teeth. NICE Technology Appraisal Guidance No.1*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the use of autologous cartilage transplantation for full thickness cartilage defects in knee joints. NICE Technology Appraisal Guidance No.16*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the use of taxanes for breast cancer. NICE Technology Appraisal Guidance No.6*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia. NICE Technology Appraisal Guidance No.7*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the use of implantable cardioverter defibrillators for arrhythmias. NICE Technology Appraisal Guidance No.11*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. NICE Technology Appraisal Guidance No.10*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Hearing disability – new advances in hearing aid technology. NICE Technology Appraisal Guidance No.8*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2000) *Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. NICE Technology Appraisal Guidance No.13*. London: National Institute for Clinical Excellence.

O'Donnell C (2000) Variation in GP referral rates: what can we learn from the literature? *Family Practice* 17 (6): 462–471.

Oliver A, Pritchard C (2000) Economic evaluations relating to diabetes: A descriptive review and their compliance with guidance. *Value in Health* 3 (Suppl 1): S7–S14.

Parkes J, Bryant J, Milne R (2000) Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review. *Health Technology Assessment* 4 (26): 1–69.

Payne N, Chilcott J, McGoogan E (2000) Liquid-based cytology for cervical screening. *Cytopathology* 11 (6): 469–470.

Payne N, Chilcott J, McGoogan E (2000) Liquid-based cytology in cervical screening: a rapid and systematic review. *Health Technology Assessment* 4 (18): 1–73.

Pollock K, Grime J (2000) Patients' views on cost effectiveness of drugs are important. *British Medical Journal* 321 (7271): 1292.

Roach J (2000) NICE recommends flu drug for "at risk" patients. *British Medical Journal* 321 (7272): 1305.

Scott G (2000) NICE agrees to reconsider beta-interferon proposals. *Nursing Standard* 15 (9): 8.

Shepherd J, Waugh N, Hewitson P (2000) Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. *Health Technology Assessment* 4 (33): 1–67.

Silver S (2000) Professor Sir Michael Rawlins – chairman of NICE. National Institute of Clinical Excellence. Interviewed by Sue Silver. *Lancet Oncology* 1: 113–117.

Simister K (2000) The role of national agencies in the managed introduction of new drugs for arthritis. *Annals of the Rheumatic Diseases* 59 (Suppl 1): i38–i40.

Smith R (2000) The failings of NICE. *British Medical Journal* 321 (7273): 1363–1364.

Song F, O'Meara S, Wilson P et al (2000) The effectiveness and cost-effectiveness of prophylactic removal of wisdom teeth. *Health Technology Assessment* 4 (15): 1–55.

Tavakoli M, Davies H, Thomson R (2000) Decision analysis in evidence-based decision making. *Journal of Evaluation in Clinical Practice* 6 (2): 111–120.

Waldron G (2000) Feedback not so NICE. *British Dental Journal* 188 (12): 644.

Walley T, Earl-Slater A, Haycox A et al (2000) An integrated national pharmaceutical policy for the United Kingdom? *British Medical Journal* 321 (7275): 1523–1526.

Welsby P (2000) Analysis by CHI of divergence from NICE-approved guidelines: how will a judgement be made between sub-optimal care and good decision skill. In: Mile A, Hampton J, Hurwitz B, editors. *NICE, CHI and the NHS reforms: enabling excellence or imposing control*. Chapter 10. London: UeL Centre for Health Services Research, p 139–152.

Weston S, Weston C (2000) Should we be nice to each other? The role of hostility in cardiovascular events. *British Journal of Cardiology* 7 (12): 745–747.

White C (2000) NICE approves taxanes for breast cancer. *British Medical Journal* 320 (7251): 1688A.

Wylie I (2000) Are NICE and CHI exactly what they are made out to be? *Doctor* 64–65.

Yamey G (2000) Drug companies seek MS patients to lobby for new products. *British Medical Journal* 320 (7229): 207.

2001

A and others v. the National Blood Authority and others (2001) EWHC QB 446.

Anonymous (2001) ABPI concern on NICE timing. *SCRIP World Pharmaceutical News* (2685): 3.

Anonymous (2001) ABPI for drug use before Nice exam. *Manufacturing Chemist* 72 (1): 4.

Anonymous (2001) ABPI to raise concerns in NICE review. *SCRIP World Pharmaceutical News* (2633): 5.

Anonymous (2001) Brain cancer drug gets the go-ahead from NICE. *Chemist Druggist*: 14.

Anonymous (2001) Caesarean rate rising steeply. *Nursing Times* 97 (43): 5.

Anonymous (2001) Consumers' Association to hold "inquiry" into NICE. *British Medical Journal* 322 (7301): 1506.

Anonymous (2001) D&TB says NICE is wrong on zanamivir recommendation. *Chemist Druggist* 10.

Anonymous (2001) DTB continues Relenza campaign. *SCRIP World Pharmaceutical News* (2620): 2.

Anonymous (2001) Firms will not cut MS prices in UK. *SCRIP World Pharmaceutical News* (2668): 2.

Anonymous (2001) Glitazones show regulatory drawbacks. *SCRIP World Pharmaceutical News* (2651): 5.

Anonymous (2001) Health authorities not monitoring compliance with NICE guidance. *Pharmaceutical Journal* 267 (7177): 807.

Anonymous (2001) Industry TAG involvement possible? *SCRIP World Pharmaceutical News* (2703): 5.

Anonymous (2001) Lung cancer drugs get the go ahead from NICE. *Chemist Druggist*: 10.

Anonymous (2001) MPs to investigate NICE. *British Medical Journal* 323 (7323): 1204.

Anonymous (2001) National Institute for Clinical Excellence. Alzheimer's drugs given go-ahead. *Nursing Times* 97 (4): 7.

Anonymous (2001) Next NICE appraisal topics. *SCRIP World Pharmaceutical News* (2643): 6.

Anonymous (2001) NICE approves Alzheimer's disease drugs. *Chemist Druggist*: 10.

Anonymous (2001) NICE clears Alzheimer's products. *SCRIP World Pharmaceutical News* (2611): 5.

Anonymous (2001) NICE clears Hycamtin for ovarian cancer. *SCRIP World Pharmaceutical News* (2667): 3.

Anonymous (2001) NICE clears Xenical. *SCRIP World Pharmaceutical News* (2625): 3.

Anonymous (2001) NICE decision welcomed, but the campaign continues. *Journal of Dementia Care* 9 (2): 6.

Anonymous (2001) NICE delays MS drugs appraisal. *SCRIP World Pharmaceutical News* (2605/6): 3.

Anonymous (2001) NICE draft rejects MS products again. *SCRIP World Pharmaceutical News* (2667): 2.

Anonymous (2001) NICE drafts guidelines for diabetes. *SCRIP World Pharmaceutical News* (2654): 6.

Anonymous (2001) NICE go-ahead for ovarian cancer drug topotecan. *Chemist Druggist*: 8.

Anonymous (2001) NICE guidance on drug treatment after MI. *Chemist Druggist*: 10.

Anonymous (2001) NICE guidance to be mandatory. *SCRIP World Pharmaceutical News* (2703): 4.

Anonymous (2001) NICE issues guidance on orlistat and pioglitazone. *Chemist Druggist*: 12.

Anonymous (2001) NICE issues sixth work programme schedule. *Chemist Druggist*: 8.

Anonymous (2001) NICE limits COX-2s to "high-risk" use. *SCRIP World Pharmaceutical News* (2665): 2.

Anonymous (2001) NICE MabThera guidance to be redrawn. *SCRIP World Pharmaceutical News* (2658).

Anonymous (2001) NICE posts draft guidance on MS treatment. *British Medical Journal* 323 (7308): 300.

Anonymous (2001) NICE publishes first clinical guidelines. *SCRIP World Pharmaceutical News* (2638): 4.

Anonymous (2001) NICE rejects Rilutek appeals. *SCRIP World Pharmaceutical News* (2616): 5.

Anonymous (2001) NICE rejects Taxotere for first-line use. *SCRIP World Pharmaceutical News* (2683): 7.

Anonymous (2001) NICE review to be conducted by UK DoH. *SCRIP World Pharmaceutical News* (2679): 6.

Anonymous (2001) NICE says Actos to save NHS 12 million pounds sterling. *SCRIP World Pharmaceutical News* (2625): 4.

Anonymous (2001) NICE seeks independence. *SCRIP World Pharmaceutical News* (2680): 5.

Anonymous (2001) NICE sets up Citizens Council. *SCRIP World Pharmaceutical News* (2700): 2.

Anonymous (2001) NICE to appraise drugs before launch. *Pharmaceutical Journal* 267 (7177): 807.

Anonymous (2001) NICE to reappraise colorectals. *SCRIP World Pharmaceutical News* (2659): 2.

Anonymous (2001) NICE to rule on Alzheimer's drugs. *Manufacturing Chemist* 72 (2): 7.

Anonymous (2001) NICE to set up new bodies. *SCRIP World Pharmaceutical News* (2619): 4.

Anonymous (2001) NICE's FAD rejects MS products. *SCRIP World Pharmaceutical News* (2693): 2.

Anonymous (2001) No NICE guidance on MS drugs yet. *Chemist Druggist*: 4.

Anonymous (2001) Novo Nordisk challenges NICE guidances. *SCRIP World Pharmaceutical News* (2631): 6.

Anonymous (2001) Quality of NICE evidence questioned. *SCRIP World Pharmaceutical News* (2640): 4.

Anonymous (2001) Scotland backs NICE on anticancers. *SCRIP World Pharmaceutical News* (2673/4): 5.

Anonymous (2001) UK CHI explains NICE remit. *SCRIP World Pharmaceutical News* (2671): 5.

- Anonymous (2001) UK committee to investigate NICE. *SCRIP World Pharmaceutical News* (2697): 4.
- Anonymous (2001) UK consumer group wants NICE review. *SCRIP World Pharmaceutical News* (2702): 5.
- Anonymous (2001) Why not zanamivir? *Drug & Therapeutics Bulletin* 39 (2): 9–10.
- Arshad P, Sridharan B, Brown R (2001) Treatment for Alzheimer's disease in people with learning disabilities: NICE guidance. *British Journal of Psychiatry* 179: 74.
- Ashraf H (2001) UK study finds wide variation in cancer surgery services. *The Lancet* 358 (9297): 1967.
- Association of the British Pharmaceutical Industry, National Institute for Clinical Excellence (2001) *NICE and medicines*. London: Association of the British Pharmaceutical Industry 2p.
- Baker M, Kirk S, Donaldson L (2001) *Research and development for the NHS; evidence, evaluation and effectiveness; edited by Mark R. Baker, and Simon Kirk*. 3rd edition. Abingdon: Radcliffe Medical Press.
- Barbour V (2001) Imatinib for chronic myeloid leukaemia: a NICE mess. *Lancet* 358 (9292): 1478.
- Barnett D (2001) Clinical effectiveness and cost effectiveness of zanamivir (Relenza): translating the evidence into clinical practice, a National Institute for Clinical Excellence view. *Philosophical Transactions of the Royal Society of London – Series B: Biological Sciences* 356 (1416): 1899–1903.
- Barnett D (2001) Riluzole for motor neurone disease. Reply from chairman of appraisal committee at NICE. *British Medical Journal* 323 (7312): 573.
- Batra N (2001) Hepatitis C screening and treatment versus liver transplantation: A financial option appraisal and commissioning model for purchasers. *Disease Management & Health Outcomes* 9 (7): 371–384.
- Beard K (2001) Systems for evaluation of new drugs in the United Kingdom. *Pharmacoepidemiology & Drug Safety* 10 (5): 439–443.
- Beattie V, Hockley B (2001) NICE gets tooled up. *British Journal of Clinical Governance* 6 (4): 231–232.
- Bellingham C (2001) Current issues in influenza. *Pharmaceutical Journal* 266 (7130) 57–59.
- Bellingham C (2001) NICE and MS: The saga will continue. *Pharmaceutical Journal* 267 (7173): 672.
- Bosanquet N (2001) NICE; involving managers in key estimates. *British Journal of Healthcare Management* 7 (5): 183–184.
- Bowens A, McDonald R, Ayres P et al (2001) The processes and costs of local guideline development: Experiences from the Path.Finder NHS consortium. *British Journal of Clinical Governance* 6 (3): 159–165.
- Bragg T (2001) Rosiglitazone and type 2 diabetes mellitus. *Lancet* 357 (9266): 1451.
- Brambleby P (2001) Should NICE's advice be handled centrally or locally? *British Medical Journal* 322 (7268): 613.
- British Association of European Pharmaceutical Distributors and Dowelhurst limited association of British Pharmaceutical Industry (2001) EWHC ADMIN 183.
- British Medical Association, General Practitioners Committee (2001) *The future of prescribing; discussion paper*. London: General Practitioners Committee British Medical Association 5p.
- Buxton M (2001) Implications of the appraisal function of the National Institute for Clinical Excellence (NICE). *Value in Health* 4 (3): 212–216.
- Charles T, Swash M (2001) Amyotrophic lateral sclerosis: current understanding. *Journal of Neuroscience Nursing*. 33 (5): 245–253.
- Chilcott J, Wight J, Lloyd J et al (2001) The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review. *Health Technology Assessment* 5 (19): 1–61.
- Clegg A, Bryant J (2001) Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. *Expert Opinion on Pharmacotherapy* 2 (4): 623–639.
- Clegg A, Bryant J, Nicholson T et al (2001) Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. *Health Technology Assessment* 5 (1): 1–137.
- Clegg A, Scott D, Sidhu M et al (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. *Health Technology Assessment* 5 (32): 1–195.
- Close N (2001) Disseminating guidelines – An effective model. *Journal of Clinical Excellence* 3 (1): 37–39.

- Collier J (2001) Zanamivir: an alternative translation. *Philosophical Transactions of the Royal Society of London – Series B: Biological Sciences* 356 (1416): 1945–1946.
- Cookson R, McDaid D, Maynard A (2001) Wrong SIGN, NICE mess: is national guidance distorting allocation of resources? *British Medical Journal* 323 (7315): 743–745.
- Dhaliwal J (2001) The failings of NICE. Editor's choice of acronym for new NICE is Punjabi for thief. *British Medical Journal* 322 (7284): 491.
- Dinnes J, Cave C, Huang S et al (2001) The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review. *Health Technology Assessment* 5 (13): 1–73.
- Dixon M (2001) *NHS Alliance manifesto* 2001. Retford: NHS Alliance 7p.
- Dobson R (2001) Obesity drug approved as problem grows across the world. *British Medical Journal* 323 (7319): 955.
- Doyle Y (2001) Equity in the new NHS: hard lessons from implementing a local healthcare policy on donepezil. *British Medical Journal* 323 (7306): 222–224.
- Dyer C (2001) Kennedy refused to read the General Medical Council's reports. *British Medical Journal* 323 (7306): 183.
- Ellis S (2001) The failings of NICE. Doctors treating patients with multiple sclerosis will lose confidence in NICE. *British Medical Journal* 322 (7284): 491.
- Farmer J, Chesson R (2001) Nice lessons to be learned. *International Journal of Technology Assessment in Health Care* 17 (2): 222–235.
- Forbes C, Shirran L, Bagnall A et al (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. *Health Technology Assessment* 5 (28): 1–110.
- Fox K (2001) A critical evaluation of the NICE guidelines for post-myocardial infarction prophylaxis. *Expert Opinion on Pharmacotherapy* 2 (12): 2079–2084.
- Freemantle N (2001) Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? *British Medical Journal* 322 (7292): 989–991.
- Gall N, Kearney M, Zaman A et al (2001) Implementation of the NICE guidelines for the primary prevention of mortality from ventricular tachyarrhythmias: implications for UK electrophysiology centres; activity modelling from the UK-HEART study. *Heart (British Cardiac Society)* 86 (2): 219–220.
- Gatehouse S (2001) Guest editorial – Some reflections on the NICE appraisal of hearing aid technology. *British Journal of Audiology* 35 (5): 267–270.
- Gatehouse S (2001) Some reflections on the NICE appraisal of hearing aid technology. National Institute for Clinical Excellence. *British Journal of Audiology* 35 (5): 267–270.
- Gibis B, Gawlik C, Sander G et al (2001) Is autologous chondrocyte implantation a technology suitable for ambulatory health care? *Zeitschrift für Ärztliche Fortbildung und Qualitätssicherung* 95 (3): 219–223.
- Goddard R (2001) Electronic fetal monitoring. Is not necessary for low risk labours. *British Medical Journal* 322 (7300): 1436–1437.
- Hart J (2001) The failings of NICE. Rationing is a respectable word for a disgraceful retreat. *British Medical Journal* 322 (7284): 490.
- Health Technology Board for Scotland (2001) *Comment on the National Institute for Clinical Excellence Technology Appraisal Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease*. Health Technology Board for Scotland.
- Health Technology Board for Scotland (2001) *Comment on the National Institute for Clinical Excellence Technology Appraisal Guidance on the use of docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer*. Health Technology Board for Scotland.
- Howlett M (2001) *The practice gap in schizophrenia*. London: The Zito Trust 8p.
- Hutchinson A, McIntosh A, Peters J et al (2001) Clinical guidelines and evidence review for Type 2 diabetes: diabetic retinopathy early management and screening. Sheffield: ScHARR, University of Sheffield 104p.
- Jack D (2001) Nice one Jean Paul! *Lancet* 358 (9293): 1656.

Jefferys D (2001) The regulation of medical devices and the role of the Medical Devices Agency. *British Journal of Clinical Pharmacology* 52 (3): 229–235.

Jobanputra P, Parry D, Fry-Smith A et al (2001) Effectiveness of autologous chondrocyte transplantation for hyaline cartilage defects in knees: a rapid and systematic review. *Health Technology Assessment* 5 (11): 1–57.

Jones A (2001) The economic evaluation of healthcare: the appliance of science. *International Journal of Medical Marketing* 1 (4): 289–298.

Kelson M (2001) Patient involvement in clinical guideline development – Where are we now? *Journal of Clinical Governance* 9 (4): 169–174.

Kennedy R, Kirk S, Gardiner K (2001) Probiotics. *British Journal of Surgery* 88 (7): 1018–1019.

Kenny D (2001) Is doctors' faith in NICE beginning to crumble? *Hospital Doctor*: 16–19.

Kmietowicz Z (2001) Government insists NHS pays for drugs approved by NICE. *British Medical Journal* 323 (7326): 1386.

Kmietowicz Z (2001) NICE approves drugs for Alzheimer's disease. *British Medical Journal* 322 (7280): 190.

Kmietowicz Z (2001) Reform of NICE needed to boost its credibility. *British Medical Journal* 323 (7325): 1324.

Knight C (2001) National Institute for Clinical Excellence guidance: too NICE to glycoprotein IIb/IIIa inhibitors? *Heart (British Cardiac Society)* 85 (5): 481–483.

Lewis R, Whiting P, ter Riet G et al (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention. *Health Technology Assessment* 5 (14): 1–131.

Lilford R, Richardson A, Stevens A et al (2001) Issues in methodological research: perspectives from researchers and commissioners. *Health Technology Assessment* 5 (8): 1–57.

Lim D, Muir J (2001) Imatinib for chronic myeloid leukaemia: a NICE mess. *Lancet* 358 (9296): 1903.

Lipman T (2001) The failings of NICE. NICE and evidence based medicine are not really compatible. *British Medical Journal* 322 (7284): 489–490.

Littlejohns P (2001) The establishment of the National Institute for Clinical Excellence: Its importance and implications for the pharmaceutical industry. *Drug Information Journal* 35 (1): 181–188.

Littlejohns P (2001) The relationship between NICE and the national R & D programme. In: Baker M, Kirk S, editors. *Research and development for the NHS: evidence, evaluation and effectiveness*. Chapter 4. Abingdon: Radcliffe Medical Press, p 39–57.

Littlejohns P, Gibbon P (2001) Evidence-based medicine: NICE hints on day-to-day implementation. *International Journal of Pharmaceutical Medicine* 15 (6): 281–286.

Lloyd J, Hummel S, Bansback N et al (2001) A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. *Health Technology Assessment* 5 (25): 1–128.

Lord J, Shaw L, Dobbs F et al (2001) A time for change and a time for equality – infertility services and the NHS. *Human Fertility (Cambridge, England)* 4 (4): 256–260.

Lovatt B, Mills F (2001) Update on the National Institute for Clinical Excellence (NICE). *Good Clinical Practice Journal* 8 (2): 16–20.

Lowery K (2001) NICE guidelines unfair for Alzheimer's disease. *British Journal of Nursing* 10 (20): 1314.

Lugon, M, Secker-Walker, J (editors) (2001) *Advancing clinical governance*. London: Royal Society of Medicine Press.

Madden V (2001) Funding issues in hepatitis C; the cost-benefit ratio. *British Journal of Healthcare Management* 7 (8): 326–328.

Manoharan G, Adgey A (2001) Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond. *Heart (British Cardiac Society)* 86 (3): 259–261.

Mason I (2001) Why cancer specialists are losing belief in NICE. *Hospital Doctor*: 21.

Matthews D (2001) Guidance on rosiglitazone for type 2 diabetes mellitus. *Lancet* 357 (9254): 481.

Mayor S (2001) Health department to fund interferon beta despite institute's ruling. *British Medical Journal* 323 (7321): 1087.

Mayor S (2001) UK body supports chemotherapy drugs for lung cancer. *British Medical Journal* 322 (7301): 1508.

McClarey M (2001) Implementing NICE guidance. *Professional Nurse* 16 (6): 1145.

McIntosh A, Hutchinson A, Home P et al (2001) *Clinical guidelines for Type 2 diabetes: management of blood glucose*. Sheffield: ScHARR, University of Sheffield 235p.

Muir J, Lim D, Brien S et al (2001) Imatinib for chronic myeloid leukaemia: a NICE mess. *The Lancet* 358 (9296): 1902.

Mulhall A, Kelly D, Pearce S (2001) Naturalistic approaches to healthcare evaluation: The case of a teenage cancer unit. *Journal of Clinical Excellence* 3 (4): 167–173.

Nathoo V (2001) Managing gastro-oesophageal reflux disease in primary care. *International Journal of Clinical Practice* 55 (7): 465–469.

National Institute for Clinical Excellence (2001) *An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast cancer*. NICE Technology Appraisal Guidance No.30. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Annual report 2000/2001 and summary financial statement*. London: National Institute for Clinical Excellence 24p.

National Institute for Clinical Excellence (2001) *Business plan 2001–2002*. London: National Institute for Clinical Excellence 55p.

National Institute for Clinical Excellence (2001) *Compilation: summary of guidance issued to the NHS in England and Wales. Issue 2*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Compilation: summary of guidance issued to the NHS in England and Wales. Issue 3*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Corporate plan 2001–2004*. London: National Institute for Clinical Excellence 38p.

National Institute for Clinical Excellence (2001) *Guidance for appellants*. London: National Institute for Clinical Excellence iii13p.

National Institute for Clinical Excellence (2001) *Guidance for healthcare professional groups*. No 4. London: National Institute for Clinical Excellence iv14p.

National Institute for Clinical Excellence (2001) *Guidance for manufacturers and sponsors*. No 5. London: National Institute for

Clinical Excellence iv31p.

National Institute for Clinical Excellence (2001) *Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)*. NICE Technology Appraisal Guidance No.23. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Guidance on the use of gemcitabine for the treatment of pancreatic cancer*. NICE Technology Appraisal Guidance No.25. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease*. NICE Technology Appraisal Guidance No.19. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia*. NICE Technology Appraisal Guidance No.29. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Guidance on the use of pioglitazone for type 2 diabetes mellitus*. NICE Technology Appraisal Guidance No.21. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Guidance on the use of laparoscopic surgery for inguinal hernia*. NICE Technology Appraisal Guidance No.18. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis*. NICE Technology Appraisal Guidance No.27. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Guidance on the use of docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer*. NICE Technology Appraisal Guidance No.26. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Guidance on the use of sibutramine for the treatment of obesity in adults*. NICE Technology Appraisal Guidance No.31. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Guidance on the use of topotecan for the treatment of advanced ovarian cancer*. NICE

Technology Appraisal Guidance No.28. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Guidance on the use of debriding agents and specialist wound care clinics for difficult to heal surgical wounds*. *NICE Technology Appraisal Guidance* No.24. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease*. *NICE Technology Appraisal Guidance* No.20. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Guide to the technology appraisal process*. No 1. London: National Institute for Clinical Excellence iii20p.

National Institute for Clinical Excellence (2001) *Guidelines on pressure ulcer risk management and prevention – guideline*. *NICE Inherited Clinical Guideline B*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Induction of labour – guideline*. *NICE Inherited Clinical Guideline D*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Information for National Collaborating Centres and guideline development groups*. No 3. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Information for the public*. No 1. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Information for stakeholders*. No 2. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) London. *NICE Technology Appraisal Guidance* No.22. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Prophylaxis for patients who have experienced a myocardial infarction: drug treatment, cardiac rehabilitation and dietary manipulation – guideline*. *NICE Inherited Clinical Guideline A*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2001) *Referral advice: a guide to appropriate referral from general to specialist services*. London: National Institute for Clinical Excellence 50p.

National Institute for Clinical Excellence (2001) *The use of electronic fetal monitoring. The use and interpretation of cardiotocography in intrapartum fetal surveillance – guideline*. *NICE Inherited Clinical Guideline C*. London: National Institute for Clinical Excellence.

National Prescribing Centre (2001) *Implementing NICE guidance: a practical handbook for professionals*. Abingdon: Radcliffe Medical Press.

Newdick C (2001) Strong words. *Health Service Journal* 111 (5749): 26–27.

O'Brien J, Ballard C (2001) Drugs for Alzheimer's disease. *British Medical Journal* 323 (7305): 123–124.

O'Brien J, Robinson L, Fairbairn A (2001) Proposed shared care protocol between primary and secondary care for the ongoing management of those on anti-dementia medication. *Primary Care Psychiatry* 7 (3): 111–113.

O'Brien S (2001) Imatinib for chronic myeloid leukaemia: a NICE mess. *Lancet* 358 (9296): 1902–1903.

O'Meara S, Riemsma R, Shirran L et al (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. *Health Technology Assessment* 5 (18): 1–81.

Ord J, Reece-Smith H (2001) The National Institute for Clinical Excellence and hernia repair. *British Journal of Surgery* 88 (7): 1018.

Paul J, Trueman P (2001) 'Fourth hurdle reviews', NICE, and database applications. *Pharmacoepidemiology & Drug Safety* 10 (5): 429–438.

Powell M (2001) The failings of NICE. Latest decision on zanamivir will not end postcode prescribing. *British Medical Journal* 322 (7284): 490.

Quennell P (2001) Getting their say, or getting their way? Has participation strengthened the patient "voice" in the National Institute for Clinical Excellence? *Journal of Management in Medicine* 15 (3): 202–219.

Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. *British Medical Journal* 323 (7324): 1300–1303.

Rajaratnam G, Edwards J (2001) Imatinib for chronic myeloid leukaemia: a NICE mess. *Lancet* 358 (9296): 1902.

Rawlins M (2001) EuroNICE: the case against. *Scip* (2701): 6–7.

Rawlins M (2001) The failings of NICE. Reply from chairman of NICE. *British Medical Journal* 322 (7284): 489.

Rawlins M, Lipman T, Hart J et al (2001) The failings of NICE. *British Medical Journal* 322 (7284): 489–491.

Robinson S, Valabhji J, Schachter M (2001) The failings of NICE. NICE's guidance suggests using rosiglitazone in type 2 diabetes later than is ideal. *British Medical Journal* 322 (7284): 491.

Royal College of Nursing (2001) *Pressure ulcer risk assessment and prevention: recommendations 2001*. London: Royal College of Nursing 36p.

Royal College of Obstetricians and Gynaecologists *Clinical Effectiveness Support Unit (2001) The use of electronic fetal monitoring: the use and interpretation of cardiotocography in intrapartum fetal surveillance*. Evidence-based clinical guideline number 8. London: Royal College of Obstetricians and Gynaecologists.

Royal College of Obstetricians and Gynaecologists Clinical Effectiveness Support Unit (2001) *Induction of labour*. Evidence-based clinical guideline number 9. London: Royal College of Obstetricians and Gynaecologists x78p.

Russell L (2001) Overview of research to investigate pressure-relieving surfaces. *British Journal of Nursing* 10 (21): 1421–1426.

Sculpher M, Drummond M, O'Brien B (2001) Effectiveness, efficiency, and NICE. *British Medical Journal* 322 (7292): 943–944.

Stanton J (2001) A nurse's aid to clinical selection of pressure-reducing equipment. *British Journal of Nursing* 10 (15 suppl): S16–S28.

Stewart A, Sandercock J, Bryan S et al (2001) The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review. *Health Technology Assessment* 5 (2): 1–97.

Stewart R (2001) NICE guidelines and the treatment of Alzheimer's disease: evidence-based medicine may be discriminatory. *British Journal of Psychiatry* 179: 367.

Sukkar E (2001) Balancing costs and clinical benefits. *SCRIP Magazine* (98): 42–44.

Sukkar E (2001) Patients want rethink on UK drug pricing. *SCRIP World Pharmaceutical News* (2679): 5.

Sukkar E (2001) What future for UK price scheme? *SCRIP World Pharmaceutical News* (2670): 2–3.

Taylor D (2001) Funding medicines for people with multiple sclerosis. *British Medical Journal* 323 (7326): 1379–1380.

Taylor E (2001) Health policy. In: Dawson J, editor. *Clinical effectiveness in nursing practice*. Chapter 2. London: Whurr Publishers, p 45–62.

Taylor G (2001) Clinical governance. In: Harrison J, editor. *The new GP: Changing roles and the modern NHS*. Chapter 9. Abingdon: Radcliffe Medical Press, p 107–117.

Taylor R (2001) Pharmaceutical regulation: the early experience of the NHS National Institute for Clinical Excellence (NICE) appraisal process – where are we headed? *Value in Health* 4 (1): 8–11.

Taylor R (2001) Using health outcomes data to inform decision-making: Government agency perspective. *Pharmacoeconomics* 19 (SUPPL. 2): 33–38.

Toynbee P, Walker D (2001) The health of health. In: Toynbee P, Walker D, editors. *Did things get better?* Chapter 4. London: Penguin Books, p 72–91.

Walker A (2001) Clinical effectiveness 2000: an overview. *Proceedings of the Royal College of Physicians of Edinburgh* 31 (Supp 9): 2–6.

Walker R (2001) The failings of NICE. "Spinning" is not nice. *British Medical Journal* 322 (7284): 490.

Ward S, Morris E, Bansback N et al (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer. *Health Technology Assessment* 5 (24): 1–70.

Werko L (2001) NICE not so nice as the name suggests. Sneaking attempt of therapeutic bureaucracy? *Lakartidningen* 98 (24): 2908–2909.

Williams A (2001) Dilemmas in health care; responding to economic constraints. In: Komaromy C, editor. *Dilemmas in UK health care*. Chapter 2. Buckingham: Oxford University Press, p 21–39.

Wise J (2001) Obesity drug endorsed by NICE. *British Medical Journal* 322 (7287): 637.

Adi Y, Ashcroft D, Browne K et al (2002) Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders. *Health Technology Assessment* 6 (28): 1–66.

Alfakih K, Hall A, Robinson M (2002) Rapid appraisal of clinicians' reactions to guidance from the National Institute of Clinical Excellence on use of glycoprotein IIb/IIIa antagonists for acute coronary syndromes. *British Journal of Cardiology* 9 (8): 476–477.

Anonymous (2002) Alzheimer's drugs "still rationed in UK". Marketletter.

Anonymous (2002) Another NICE mess. *Lancet Oncology* 3 (7): 385.

Anonymous (2002) Antipsychotics guidance out. *Chemist Druggist*: 4.

Anonymous (2002) Bigger rule for auditor of NICE uptake. *SCRIP World Pharmaceutical News* (2751): 5.

Anonymous (2002) Cancer drug approved by NICE. *British Medical Journal* 325 (7360): 354.

Anonymous (2002) Cancer specialists seek review of NICE decision on colorectal cancer drugs. *Pharmaceutical Journal* 268 (7202): 827.

Anonymous (2002) Cannabinoids are referred to NICE for appraisal. *Chemist Druggist*: 9.

Anonymous (2002) Comment from the Editor. *Chemist Druggist*: 12.

Anonymous (2002) Does NICE need unpublished data? *SCRIP World Pharmaceutical News* (2808): 5.

Anonymous (2002) Funding smoking cessation is a NICE move. *Pharmaceutical Business News* (412): 5.

Anonymous (2002) 'Give early thrombolysis treatment to MI patients'. *GP*: 4.

Anonymous (2002) Glivec to be restricted in the UK? *SCRIP World Pharmaceutical News* (2747): 5.

Anonymous (2002) Herceptin approved by NICE. *Pharmaceutical Business News* (410): 3.

Anonymous (2002) Insulin glargine an option for diabetes, says NICE. *Pharmaceutical Journal* 269 (7228): 836.

Anonymous (2002) Is NICE now in limbo? *Pharmaceutical Journal* 268 (7184): 160.

Anonymous (2002) Lord Hunt hints at more MS-type deals. *SCRIP World Pharmaceutical News* (2728): 6.

Anonymous (2002) Ministers will intervene on NICE uptake. *SCRIP World Pharmaceutical News* (2806): 5.

Anonymous (2002) National Institute for Clinical Excellence (NICE): symposium on technology assessment. *International Journal of Technology Assessment in Health Care* 18 (2): 159–212.

Anonymous (2002) New non-executive director appointed to NICE. *British Medical Journal* 325 (7368): 792.

Anonymous (2002) NICE adding to inadequate situation for AMD treatment. *Pharmaceutical Business News* (409): 3.

Anonymous (2002) NICE advises on diabetes. *Chemist Druggist*: 27.

Anonymous (2002) NICE advises on surgery for morbid obesity. *British Medical Journal* 325 (7357): 180.

Anonymous (2002) NICE and SIGN to work together. *Pharmaceutical Journal* 268 (7195): 560.

Anonymous (2002) NICE announces members of UK's first Citizens Council. *British Medical Journal* 325 (7373): 1130.

Anonymous (2002) NICE approves anti-D prophylaxis. *Pharmaceutical Journal* 268 (7198): 675.

Anonymous (2002) NICE approves ultrasound-guided catheterisation. *Clinica* (1029): 4.

Anonymous (2002) NICE approves use of trastuzumab for HER2 positive advanced breast cancer. *Pharmaceutical Journal* 268 (7190): 386.

Anonymous (2002) NICE backs atypical antipsychotics. *SCRIP World Pharmaceutical News* (2754): 2.

Anonymous (2002) NICE backs Aventis' Lantus. *SCRIP World Pharmaceutical News* (2807): 5.

Anonymous (2002) NICE backs NRT and Zyban for committed quitters. *Chemist Druggist*: 9.

Anonymous (2002) NICE backs TNF-alpha blockers for rheumatoid arthritis. *SCRIP World Pharmaceutical News* (2732): 4.

Anonymous (2002) NICE changes mind on Glivec. *SCRIP World Pharmaceutical News* (2772): 2.

Anonymous (2002) NICE citizens council selected. *Pharmaceutical Journal* 269 (7224): 705.

Anonymous (2002) NICE confirms Lantus decision. *SCRIP World Pharmaceutical News* (2793): 5.

Anonymous (2002) NICE defends itself against criticism. *SCRIP World Pharmaceutical News* (2717): 4.

Anonymous (2002) NICE guidance will be paramount. *Pharmaceutical Journal* 268 (7182): 82.

Anonymous (2002) NICE ignores Navelbine appeal ruling? *SCRIP World Pharmaceutical News* (2809/10): 4.

Anonymous (2002) NICE is "flawed", say consumer groups. *British Journal of Nursing* 11 (2): 80.

Anonymous (2002) NICE issues diabetes guidance. *Chemist Druggist*: 19.

Anonymous (2002) NICE launches schizophrenia guidelines. *Pharmaceutical Journal* 269 (7227): 799.

Anonymous (2002) NICE makes recommendations for use of thrombolytic drugs for acute MI. *Pharmaceutical Journal* 269 (7222): 633.

Anonymous (2002) NICE OKs Remicade for Chron's. *SCRIP World Pharmaceutical News* (2744/45): 5.

Anonymous (2002) NICE opts for MabThera. *Chemist Druggist*: 28.

Anonymous (2002) NICE panel rejects MS appeals. *Pharmaceutical Journal* 268 (7183): 125.

Anonymous (2002) NICE prefers Caelyx to Hycamtin. *SCRIP World Pharmaceutical News* (2720): 5.

Anonymous (2002) NICE proposes next treatment reviews. *British Medical Journal* 325 (7362): 460.

Anonymous (2002) NICE recommendations on colorectal cancer drugs merit review, says DTB. *Pharmaceutical Journal* 269 (7208): 127.

Anonymous (2002) NICE recommends growth hormone. *Pharmaceutical Journal* 268 (7200): 754.

Anonymous (2002) NICE recommends Schering-Plough cancer drug. *M2 Europharma*.

Anonymous (2002) NICE seeks clinical pharmacists for appraisal committee. *Pharmaceutical Journal* 269 (7206): 87.

Anonymous (2002) NICE states that MS drugs are not cost-effective. *Pharmaceutical Journal* 268 (7184): 163.

Anonymous (2002) NICE still limiting Visudyne use. *SCRIP World Pharmaceutical News* (2790): 2.

Anonymous (2002) NICE takes on newest procedures – and screening? *Clinica* (994): 7.

Anonymous (2002) NICE to appraise Iressa for NSCLC. *SCRIP World Pharmaceutical News* (2778): 4.

Anonymous (2002) NICE to publish guidance the same day each month. *SCRIP World Pharmaceutical News* (2790): 5.

Anonymous (2002) NICE to reappraise adult somatropin. *SCRIP World Pharmaceutical News* (2797): 3.

Anonymous (2002) NICE to take advice from the public. *Pharmaceutical Journal* 269 (7212): 237.

Anonymous (2002) NICE Visudyne decision attacked. *SCRIP World Pharmaceutical News* (2756): 7.

Anonymous (2002) NICE will cave in on PDT, says RNIB. *Optician*: 1.

Anonymous (2002) NICE work in nasty conditions. *Pharmaceutical Journal* 269 (7221): 592.

Anonymous (2002) No NICE backing for Lysovir. *SCRIP World Pharmaceutical News* (2790): 3.

Anonymous (2002) Novartis will not cut Glivec's price. *SCRIP World Pharmaceutical News* (2751): 3.

Anonymous (2002) Ovarian cancer treatment for second-line use endorsed by NICE. *Pharmaceutical Journal* 269 (7208): 122.

Anonymous (2002) Research briefs: New guidelines on use of Imatinib. *GP*: 4.

Anonymous (2002) UK and France meet on health and NICE. *SCRIP World Pharmaceutical News* (2725): 3.

Anonymous (2002) UK committee's plan on NICE data "unjustified"? *SCRIP World Pharmaceutical News* (2776/77): 3.

Anonymous (2002) UK doctors attack NICE cancer decision. *SCRIP World Pharmaceutical News* (2755): 4.

- Anonymous (2002) UK MPs want early NICE appraisals. *SCRIP World Pharmaceutical News* (2760): 2.
- Anonymous (2002) UK report backs NICE concerns. *SCRIP World Pharmaceutical News* (2740): 4.
- Anonymous (2002) UK risk-sharing deal for MS products. *SCRIP World Pharmaceutical News* (2718): 2.
- Anonymous (2002) Views sought over NICE topics' choice. *Pharmaceutical Journal* 268 (7188): 315.
- Anonymous (2002) What's so special about trastuzumab? *Drug & Therapeutics Bulletin* 40 (9): 65–67.
- Anton C (2002) Statins as the new aspirin. National Institute for Clinical Excellence should assess statins. *British Medical Journal* 324 (7340): 789.
- Ashraf H (2002) UK drug regulator to consider cannabis for patients with multiple sclerosis. *The Lancet* 359 (9307): 684.
- Bardell E (2002) Cox-2 inhibitors: implementation the NICE guidance. *Rheumatology* 41 (5): 590–592.
- Bennett C (2002) Loss of vision. *Optician*: 3.
- Birch S, Gafni A (2002) On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. *Health Economics* 11 (3): 185–191.
- Blackmore H (2002) NICE Interventional Procedures Programme. Welsh health circular. WHC(02)119. Cardiff: National Assembly for Wales 3p.
- Brada M (2002) NICE verdict on Temozolomide: where next? *British Journal of Cancer* 86 (4): 499–500.
- Bryan J (2002) Bitter pills. *Pharmaceutical Industry Guide* 112 (supp 1): 1–3.
- Bryant J, Loveman E, Chase D et al (2002) Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation. *Health Technology Assessment* 6 (19): 1–106.
- Bullock R (2002) New drugs for Alzheimer's disease and other dementias. *British Journal of Psychiatry* 180: 135–139.
- Burke K (2002) NICE may fail to stop "postcode prescribing," MPs told. *British Medical Journal* 324 (7331): 191.
- Burke K (2002) NICE needs sweeping changes to maintain credibility, say MPs. *British Medical Journal* 325 (7354): 5.
- Burke K (2002) No cash to implement NICE, health authorities tell MPs. The National Institute for Clinical Excellence. *British Medical Journal* 324 (7332): 258.
- Burls A, Clark W, Stewart T et al (2002) Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. *Health Technology Assessment* 6 (9): 1–87.
- Calvert R (2002) Medicines management. Fit to bust. *Health Service Journal* 112 (5826): 24–25.
- Cameron A (2002) Why does NICE not recommend laparoscopic herniorrhaphy? Article implies that vested interest and prejudice operate. *British Medical Journal* 325 (7359): 339.
- Cameron D, Dixon J (2002) Postcode prescribing is alive and well in Scotland. *British Medical Journal* 325 (7355): 101.
- Cantrill J (2002) The first 18 months of primary care groups: Pharmaceutical implications. *Pharmaceutical Journal* 268 (7190): 407–409.
- Cassidy J, Bridgewater J, Mainwaring P et al (2002) Is the NICE process flawed? *Lancet* 359 (9323): 2119–2120.
- Claxton K, Sculpher M, Drummond M (2002) A rational framework for decision making by the National Institute For Clinical Excellence (NICE). *Lancet* 360 (9334): 711–715.
- Clegg A, Colquitt J, Sidhu M et al (2002) The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. *Health Technology Assessment* 6 (12): 1–153.
- Cohen H (2002) *The use of cox II non-steroidal anti-inflammatory drugs in a district general hospital compared against National Institute of Clinical Excellence guidelines*. Presented at EULAR 2002 (Stockholm), 12 Jun 2002.
- Comerford C, Evans P (2002) The changing face of rationing. *Doctor*: 50–59.
- Coote A, Appleby J (2002) Permanent revolution. *Stakeholder* 6 (2): 12–13.
- Copeland R (2002) Implementation of NICE guidance: Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. *Pharmacy in Practice* 12 (3): 119–126.

- Corrie P (2002) Is NICE being nice to patients with digestive cancers? *Gastrointestinal Oncology* 4 (1): 1–4.
- Cowan P (2002) The role of clinical audit in risk reduction. *British Journal of Clinical Governance* 7 (3): 220–223.
- Cowper A (2002) More pursuit of better performance. *British Journal of Healthcare Management* 8 (5): 172–175.
- Cummins C, Connock M, Fry-Smith A et al (2002) A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. *Health Technology Assessment* 6 (17): 1–43.
- Davey P (2002) National guidance and allocation of resources: Economics has both strengths and weaknesses in health resource allocation. *British Medical Journal* 324 (7334): 427–428.
- Davies E (2002) Getting attached to NICE. *British Medical Journal* 325 (7377): 201s.
- Davies E, Littlejohns P (2002) Views of directors of public health about NICE appraisal guidance: results of a postal survey. *Journal of Public Health Medicine* 24 (4): 319–325.
- Dent T, Sadler M (2002) From guidance to practice: Why NICE is not enough. *British Medical Journal* 324 (7341): 842–845.
- Department of Health (2002) *Cost effective provision of disease modifying therapies for people with multiple sclerosis*. London: Department of Health 3p.
- Department of Health (2002) *National Health Service Act 1977; further directions (No. 2) to Strategic Health Authorities, Primary Care Trusts and NHS Trusts in England concerning guidance from the National Institute for Clinical Excellence (NICE)*. Leeds: Department of Health 2p.
- Department of Health, National Assembly for Wales (2002) *Clinical guidance from the National Institute for Clinical Excellence: timing and selection of topics for appraisal*. London: Department of Health 17p.
- Department of Health, Parliament, House of Commons et al (2002) *Government response to the Health Committee's second report of session 2001–02 on the National Institute for Clinical Excellence*. London: The Stationery Office 16p.
- Dillon A (2002) National Institute for Clinical Excellence. *Journal of Clinical Excellence* 4 (1 suppl): 60–61.
- Dillon A (2002) Opening the doors on NICE; the next steps. *British Journal of Healthcare Management* 8 (3): 96–97.
- Dinnes J, Cave C, Huang S et al (2002) A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. *British Journal of Cancer* 86 (4): 501–505.
- Dowd A (2002) Eyeing up the experts. *Nursing Times* 98 (35): 13.
- Drummond M (2002) Nasty or NICE? The formal requirements for economic evaluation of pharmaceuticals in England and Wales. *Pharmaceutical News* 9 (1): 57–62.
- Dyer O (2002) Oncologists protest about NICE's decision on cancer drugs. *British Medical Journal* 324 (7351): 1413.
- Eaton L (2002) NICE accused of restricting treatment for eye patients. *British Medical Journal* 325 (7369): 852.
- Ellis S (2002) Bad decision NICE. *Lancet* 359 (9304): 447.
- Evans H (2002) *National Institute for Clinical Excellence. timing and selection of topics for appraisal*. Welsh health circular. no WHC(02)31. Wales: National Assembly.
- Feinmann J (2002) How to limit caesareans on demand – too NICE to push? *Lancet* 359 (9308): 774.
- Foot B, Foy R, Chakravarthy U et al (2002) A new health technology: where is the consensus on a clinically worthwhile benefit? *Eye* 16 (4): 469–471.
- Forbes C, Wilby J, Richardson G et al (2002) A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer. *Health Technology Assessment* 6 (23): 1–119.
- Franks A (2002) Legal, decent and honest? Are quality assurance and rationing inseparable? *British Journal of Clinical Governance* 7 (1): 34–39.
- Freemantle N, Bloor K, Eastaugh J (2002) A fair innings for NICE? *Pharmacoeconomics* 20 (6): 389–391.
- Gadhok K (2002) Delivering the research and clinical effectiveness agenda; what the allied health professions can offer. *Journal of Clinical Excellence* 4 (1): 121–124.
- Garner S, Fidan D, Frankish R et al (2002) Rofecoxib for the treatment of rheumatoid arthritis (Cochrane Review). *Cochrane Database of Systematic Reviews* 3.

Garside R, Round A, Dalziel K et al (2002) The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review. *Health Technology Assessment* 6 (33): 1–162.

Gershlick A (2002) Intracoronary stenting: developments since the NICE report. *Heart (British Cardiac Society)* 87 (3): 187–190.

Godfrey C, Fowler G (2002) Pharmacoeconomic considerations in the management of smoking cessation. *Drugs* 62 (Suppl 2): 63–70.

Goldman J, Apperley J, Clark R et al (2002) Not so NICE for CML. *Lancet* 359 (9322): 2036.

Goodman N (2002) Nice. *British Journal of General Practice* 52 (474): 85.

Goodwin D, Higginson I, Myers K et al (2002) What is palliative day care? A patient perspective of five UK services. *Supportive Care in Cancer* 10 (7): 556–562.

Griffiths S (2002) Prioritizing care in a resource-limited health service. *Current Paediatrics* 12 (6): 481–486.

Gulland A (2002) NICE proposals for citizens council condemned by patients. National Institute for Clinical Excellence. *British Medical Journal* 325 (7361): 406.

Gutmann A, Thompson D (2002) Deliberative democracy beyond process. *Journal of political philosophy* 10 (2): 153–174.

Gutmann A, Thompson D (2002) Democratic decisions about health care; Why be like NICE? In: New B, Neuberger J, editors. *Hidden Assets: Values and decision-making in the NHS*. Chapter 9. London: King's Fund Publishing, p 111–128.

Harvey T (2002) A NICE little earner, but what's the gain? *British Journal of Health Care Management* 8 (9): 350.

Hawkes N (2002) Still much to prove. *House Magazine* 28 (1014): 30–32.

Hawkes, N (2002) Hundreds die as NHS fails child epileptics. The Times. p1.

Hawkes, N (2002) Patients are denied life-saving cancer drug. The Times. p3.

Hawkes, N (2002) Smokers offered drug treatment on NHS. The Times. p13.

Homa P (2002) Commission for Health Improvement. *Journal of Clinical Excellence* 4 (1): 62–63.

House of Commons Health Committee (2002) *National Institute for Clinical Excellence: Second report of session 2001–02*. HC 515–I edition. London: Stationary Office.

Howard R, Orrell R (2002) Management of motor neurone disease. *Postgraduate Medical Journal* 78 (926): 736–741.

Hunt L (2002) Lord Hunt announces changes to NICE. *Pharmaceutical Journal* 269 (7228): 839.

Hutchinson A, McIntosh A, Griffiths C et al (2002) *Clinical guidelines and evidence review for Type 2 diabetes: blood pressure management*. Sheffield: SchARR, University of Sheffield 110p.

Hyde C, Wake B, Bryan S et al (2002) Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment. *Health Technology Assessment* 6 (2): 1–89.

Jobanputra P, Barton P, Bryan S et al (2002) The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. *Health Technology Assessment* 6 (21): 1–110.

Johnson S (2002) NICE or nasty? National Institute of Clinical Excellence. *Clinical Oncology (Royal College of Radiologists)* 14 (2): 86–88.

Jorenby D (2002) Clinical efficacy of bupropion in the management of smoking cessation. *Drugs* 62 (Suppl 2): 25–35.

Kaltenthaler E, Shackley P, Stevens K et al (2002) A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety. *Health Technology Assessment* 6 (22): 1–89.

Kernick D (2002) Beta interferon, NICE, and rationing. *British Journal of General Practice* 52 (482): 784–785.

Kmietowicz Z (2002) NICE widens patient group for leukaemia drug. *British Medical Journal* 325 (7369): 852.

Kobelt G (2002) *Health economics; an introduction to economic evaluation*. 2nd edition. London: Office of Health Economics.

Langman M, Mavros P, Kong S (2002) *Determinants of initiation of cox-2 inhibitors versus NSAIDs and concurrent use of gastroprotective agents in the UK*. Presented at EULAR 2002 (Stockholm), 12 Jun 2002.

Lewis R, Bagnall A, Forbes C et al (2002) The clinical effectiveness of trastuzumab for breast cancer: a systematic review. *Health Technology Assessment* 6 (13): 1–71.

Lewis R, Bagnall A, King S et al (2002) The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation. *Health Technology Assessment* 6 (14): 1–269.

Mace S, Taylor D (2002) Adherence to NICE guidance for the use of anticholinesterases for Alzheimer's disease. *Pharmaceutical Journal* 269: 680–681.

Madhok R, Taylor A, Soltani H et al (2002) NICE and LICE: Lessons from a health district. *Journal of Public Health Medicine* 24 (1): 2–5.

Martin T, Dover S (2002) NICE guidelines? *British Dental Journal* 193 (11): 609 [letter].

Mason G, Glanville T (2002) Guidelines for antenatal anti-D prophylaxis. *Lancet* 360 (9336): 880.

Mason J, Wilson D, Nicolson D (2002) The National Guideline Support and Research Unit: Its role and aims. *Journal of Clinical Excellence* 4 (1 suppl): 200–201.

Mayor S (2002) Doctors condemn NICE's guidance on leukaemia drug. *British Medical Journal* 324 (7350): 1352.

Mayor S (2002) NICE estimates that its recommendations have cost the NHS £575m. *British Medical Journal* 325 (7370): 924a.

Mayor S (2002) NICE recommends greater use of thrombolytics in acute myocardial infarction. *British Medical Journal* 325 (7372): 1057.

Mayor S (2002) People with schizophrenia must have a say in their treatment. *British Medical Journal* 325 (7376): 1317.

Mccomb J, Camm A (2002) Primary prevention of sudden cardiac death using implantable cardioverter defibrillators; more patients need to be screened and treated. *British Medical Journal* 325 (7372): 1050–1051.

McCormack T (2002) Early thrombolysis for the treatment of acute myocardial infarction. Who will provide this treatment in the UK? Part 1. *British Journal of Cardiology* 9 (9): 549–552.

McIntosh A, Hutchinson A, Marshall S et al (2002) *Clinical guidelines and evidence review for Type 2 diabetes: renal disease prevention and early management*. Sheffield: ScHARR, University of Sheffield 182p.

McNulty C, Gammie S, Weinberg J (2002) Antibiotic guidance on the web: An opportunity for open review. *Journal of Antimicrobial Chemotherapy* 49 (4): 667–669.

Motson R (2002) Erratum: Why does NICE not recommend laparoscopic herniorrhaphy? *British Medical Journal* 325 (7369): 900.

Motson R (2002) Why does NICE not recommend laparoscopic herniorrhaphy? *British Medical Journal* 324 (7345): 1092–1094.

Muhm M (2002) Ultrasound guided central venous access. *British Medical Journal* 325 (7377): 1373–1374.

Murray K (2002) NICE to implement new wound care guidelines. *Nursing Standard* 16 (37): 6.

National Health Service for England and Wales (2002) The National Institute for Clinical Excellence (Establishment and Constitution) Amendment Order 2002. No. 1760.

National Health Service for England and Wales (2002) The National Institute for Clinical Excellence (Amendment) Regulations 2002. No. 1759 p16(2)–126(4).

National Institute for Clinical Excellence (2002) *Annual report 2001/2002 and summary financial statement*. London: National Institute for Clinical Excellence 27p.

National Institute for Clinical Excellence (2002) *Business Plan 2002–2003*. London: National Institute for Clinical Excellence 36p.

National Institute for Clinical Excellence (2002) *Compilation: summary of guidance issued to the NHS in England and Wales*. Issue 5. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Compilation: summary of guidance issued to the NHS in England and Wales*. Issue 4. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Corporate plan 2002–2005*. London: National Institute for Clinical Excellence 27p.

National Institute for Clinical Excellence (2002) *Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure*. NICE Technology Appraisal Guidance No.48. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation*. NICE Technology Appraisal Guidance No.39. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of infliximab for Crohn's disease. NICE Technology Appraisal Guidance No.40.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. NICE Technology Appraisal Guidance No.36.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine. NICE Technology Appraisal Guidance No.53.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. NICE Technology Appraisal Guidance No.33.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of computerised cognitive behavioural therapy for anxiety and depression. NICE Technology Appraisal Guidance No.51.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of routine antenatal anti-D prophylaxis for RhD-negative women. NICE Technology Appraisal Guidance No.41.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of surgery to aid weight reduction for people with morbid obesity. NICE Technology Appraisal Guidance No.46.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of metal on metal hip resurfacing arthroplasty. NICE Technology Appraisal Guidance No.44.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. NICE Technology Appraisal Guidance No.35.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. NICE Technology Appraisal Guidance No.43.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of ultrasound locating devices for placing central venous catheters. NICE Technology Appraisal Guidance No.49.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction. NICE Technology Appraisal Guidance No.52.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of beta interferon and glatiramer acetate for the treatment of multiple sclerosis. NICE Technology Appraisal Guidance No.32.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of vinorelbine for the treatment of advanced breast cancer. NICE Technology Appraisal Guidance No.54.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of pegylated liposomal doxorubicin hydrochloride (PLDH) for the treatment of advanced ovarian cancer. NICE Technology Appraisal Guidance No.45.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of trastuzumab for the treatment of advanced breast cancer. NICE Technology Appraisal Guidance No.34.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of imatinib for chronic myeloid leukaemia. NICE Technology Appraisal Guidance No.50.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of paclitaxel in the treatment of ovarian cancer. NICE Technology Appraisal Guidance No.55.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes. NICE Technology Appraisal Guidance No.47.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of human growth hormone (somatropin) in children with growth failure. NICE Technology Appraisal Guidance No.42.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Guidance on the use of rituximab for recurrent or refractory stage III or IV follicular non-Hodgkin's lymphoma*. NICE Technology Appraisal Guidance No.37. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)*. NICE Technology Appraisal Guidance No.38. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Management of type II diabetes. Renal disease – prevention and early management – guideline*. NICE Inherited Clinical Guideline F. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Management of type II diabetes. Management of blood pressure and blood lipids*. NICE Inherited Clinical Guideline H. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Management of type II diabetes. Retinopathy – screening and early management – guideline*. NICE Inherited Clinical Guideline E. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Management of type II diabetes. Management of blood glucose*. NICE Inherited Clinical Guideline G. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *National clinical audit of epilepsy-related death*. London: National Institute for Clinical Excellence 14p.

National Institute for Clinical Excellence (2002) *Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care*. NICE Clinical Guideline No.1. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2002) *Scope for the development of a clinical guideline on intentional self-harm for use in the NHS in England and Wales*. National Institute for Clinical Excellence 7p.

Neuberger J, New B (2002) *Hidden assets; values and decision-making in the NHS*. London: King's Fund Publishing.

NHS Modernisation Agency, National Institute for Clinical Excellence (2002) *Protocol-based care...underpinning improvement*.

O'Dowd A (2002) National Institute for Clinical Excellence: eyeing up the experts. *Nursing Times* 98 (35): 13.

Oliver A (2002) Unintended consequences of applying economic evaluation. *Journal of Health Services & Research Policy* 7 (3): 129–130.

Oliver A, Healey A, Donaldson C (2002) Choosing the method to match the perspective; economic assessment and its implications for health-services efficiency. *Lancet* 359 (9319): 1771–1774.

Oliver, A (editor) (2003) *Health care priority setting: implications for health inequalities. Proceedings from a meeting of the Health Equity Network*. London: Nuffield Trust.

O'Meara S, Riemsma R, Shirran L et al (2002) The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. *Health Technology Assessment* 6 (6): 1–97.

Palmer L (2002) The National Institute for Clinical Excellence and the RCM. *RCM Midwives Journal* 5 (8): 260–261.

Pellowe C, MacRae E, Loveday H et al (2002) The scope of guidelines to prevent healthcare-associated infections. *British Journal of Community Nursing* 7 (7): 374–378.

Peters J, Stevenson M, Beverley C et al (2002) The clinical effectiveness and cost-effectiveness of inhaler devices used in the routine management of chronic asthma in older children: a systematic review and economic evaluation. *Health Technology Assessment* 6 (5): 1–167.

Pfizer Ltd., R (on the application of) v Secretary of State for Health (2002) EWCA Civ 1566.

Phipps A, O'Brien J (2002) Memory clinics and clinical governance – A UK perspective. *International Journal of Geriatric Psychiatry* 17 (12): 1128–1132.

Plumb J, Edwards S (2002) Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis. *Journal of Medical Economics* 5: 25–38.

Poole-Wilson P (2002) NICE: guessing is not guidance. National Institute for Clinical Excellence. *Heart (British Cardiac Society)* 87 (6): 510–512.

Quinn T (2002) NICE announce audit of secondary prevention guidance. *British Journal of Cardiology* 9 (5): 303–304.

Rawlins M (2002) National Institute of Clinical Excellence: Clinical excellence 2002. *Journal of Clinical Excellence* 4 (3 suppl).

- Rawlins M, Kumar P (2002) National Institute of Clinical Excellence. Clinical excellence 2001. *Journal of Clinical Excellence* 4 (1 suppl).
- Rawlins, M (editor) (2002) *Progress in excellence: clinical excellence 2002.*, 2 Dec 2002. p 263–373.
- Robinson M, Ginnelly L, Sculpher M et al (2002) A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists. *Health Technology Assessment* 6 (25): 1–160.
- Rodgers A-T (2002) NICE and clinical guidelines. *Journal of Clinical Governance* 10 (4): 209–210.
- Rodgers A-T (2002) The National Institute for Clinical Excellence (NICE). *Annals of the Rheumatic Diseases* 61 (SUPPL. 2): ii92–ii95.
- Roe M (2002) Maximising the benefits to patients. *House Magazine* 27 (1002): 16.
- Royal College of Nursing, RCN Institute, Clinical Governance Research and Development Unit – University of Leicester et al (2002) *Principles for best practice in clinical audit*. Abingdon: Radcliffe Medical Press ix196p.
- Rutten F, Brouwer W (2002) More care for a limited budget; a case for a better use of the efficiency criterion. *Nederlands Tijdschrift voor Geneeskunde* 146 (47): 2254–2258.
- Saunders M, Valle J (2002) Why hasn't the National Institute been 'NICE' to patients with colorectal cancer? *British Journal of Cancer* 86 (11): 1667–1669.
- Sherbourne K, White L, Fortnuni H (2002) Intensive rehabilitation programmes for deafened men and women: an evaluation study. *International Journal of Audiology* 41 (3): 195–201.
- Slim K (2002) Why does NICE not recommend laparoscopic herniorrhaphy? French institute and NICE arrived at similar conclusions. National Institute for Clinical Excellence. *British Medical Journal* 325 (7359): 339.
- Smy J (2002) Special Report – Is NICE working?; how NICE is viewed by the medical profession. *Doctor*: 54–57.
- Stuart I (2002) Cardiotocography v Doppler auscultation. Evidence is not as good as NICE suggests. *British Medical Journal* 324 (7335): 484–485.
- Sukkar E (2002) New head for Welsh drug group. *SCRIP World Pharmaceutical News* (2783): 4.
- Syrett K (2002) Nice Work? Rationing, Review and the 'Legitimacy Problem' in the New NHS. *Medical Law Review* 10 (1): 1–27.
- Tait D (2002) Prescriber survey: can we implement NICE guidance? *Prescriber* October 2002: 49–53.
- Taylor R (2002) National Institute for Clinical Excellence (NICE). HTA rhyme and reason? *International Journal of Technology Assessment in Health Care* 18 (2): 166–170.
- Taylor R, Hutton J, Culyer A (2002) Developing the revised NICE appraisal technical guidance to manufacturers and sponsors: Opportunity or threat? *Pharmacoeconomics* 20 (15): 1031–1038.
- Thapar A, Thapar A (2002) Is primary care ready to take on Attention Deficit Hyperactivity Disorder? *BMC Family Practice* 3 (1): 7.
- Thompson A (2002) Variation may be good for your health: the nature of evidence. *International Journal of Quality in Health Care* 14 (1): 1–3.
- Thomson J, Mackintosh A, Barth J (2002) Troponin for acute coronary syndromes: has NICE got it right? *Annals of Clinical Biochemistry* 39 (Pt 3): 194–195.
- Tingle J (2002) Do guidelines have legal implications? *Archives of Disease in Childhood* 86 (6): 387–388.
- Toms A, Jiggins M, Prosser G et al (2002) NICE hips: Shame about the conclusions. *Hip International* 12 (3): 334–337.
- Towse A, Pritchard C (2002) National Institute for Clinical Excellence (NICE): Is economic appraisal working? *Pharmacoeconomics* 20 (SUPPL. 3): 95–105.
- Towse, A, Pritchard, C, and Devlin, N (editors) (2002) *Cost-effectiveness thresholds: economic and ethical issues*. London: King's Fund.
- Vale L, Wyness L, McCormack K et al (2002) A systematic review of the effectiveness and cost-effectiveness of metal-on-metal hip resurfacing arthroplasty for treatment of hip disease. *Health Technology Assessment* 6 (15): 1–109.
- Vass A (2002) NICE guidance "a real victory" for people with schizophrenia. National Institute for Clinical Excellence. *British Medical Journal* 324 (7351): 1413.
- Wake B, Hyde C, Bryan S et al (2002) Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. *Health Technology Assessment* 6 (3): 1–85.

Walshe K (2002) The rise of regulation in the NHS. *British Medical Journal* 324 (7343): 967–970.

Wanless D (2002) *Securing Our Future Health: Taking A Long-Term View*. London: HM Treasury 164p.

Waters J, O'Brien M (2002) The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). *British Journal of Cancer* 87 (5): 481–490.

Watkin D, Cameron A, Slim K (2002) Why does NICE not recommend laparoscopic herniorrhaphy? *British Medical Journal* 325 (7359): 339–340.

Watts G (2002) The chosen few. *Pharmaceutical Industry Guide* 112 (supp 1): 10–11.

Weatherly H, Drummond M, Smith D (2002) Using evidence in the development of local health policies: Some evidence from the United Kingdom. *International Journal of Technology Assessment in Health Care* 18 (4): 771–781.

Weiner J (2002) Something 'nice' can come out of this. *Managed Care* 11 (1): 30–32.

Westcott K, Irvine G (2002) Appropriateness of referrals for removal of wisdom teeth. *British Journal of Oral & Maxillofacial Surgery* 40 (4): 304–306.

Woods K (2002) Health technology assessment for the NHS in England and Wales. *International Journal of Technology Assessment in Health Care* 18 (2): 161–165.

Woolacott N, Jones L, Forbes C et al (2002) The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. *Health Technology Assessment* 6 (16): 1–245.

Working Group on CFS/ME, Department of Health (2002) Government response to the CFS/ME independent Working Group's report. Leeds: Department of Health 3p.

2003

Anonymous (2003) Delays to changing NICE appeal process. *SCRIP World Pharmaceutical News* (2839): 3.

Anonymous (2003) Glitazones in the spotlight. (Brief Article). *Chemist Druggist*: 25.

Anonymous (2003) Heart matters. *Community Pharmacy*: 23.

Anonymous (2003) New topic selection process for NICE. *SCRIP World Pharmaceutical News* (2811/12): 6.

Anonymous (2003) NICE approves imatinib. *British Medical Journal* 327 (7421): 946.

Anonymous (2003) NICE backs Glivec as first-line therapy for CML. *SCRIP World Pharmaceutical News* (2860): 5.

Anonymous (2003) NICE Citizens Council publishes discussion document on age. *British Medical Journal* 327 (7408): 180.

Anonymous (2003) NICE continues to limit insulin pump use. *SCRIP World Pharmaceutical News* (2822): 5.

Anonymous (2003) NICE FAD backs use of seven "newer" antiepileptics on NHS in England/Wales. *Pharma Marketletter*.

Anonymous (2003) NICE gives final guidance on liquid-based cytology tests. *Diagnostics Imaging Week* 6 (43): 1–2.

Anonymous (2003) NICE issues draft guidance on IVF. *British Medical Journal* 327 (7413): 466.

Anonymous (2003) NICE issues draft guidance on MabThera. *SCRIP World Pharmaceutical News* (2857): 5.

Anonymous (2003) NICE issues Tamiflu prophylaxis final draft. *SCRIP World Pharmaceutical News* (2874): 4.

Anonymous (2003) NICE limits somatropin use in adults. *SCRIP World Pharmaceutical News* (2830): 6.

Anonymous (2003) NICE plans for diabetes help. *Community Pharmacy*: 21.

Anonymous (2003) NICE recommends structured education for diabetics. *Chemist Druggist*: 26.

Anonymous (2003) NICE supports Xeloda in breast cancer. *SCRIP World Pharmaceutical News* (2815): 6.

Anonymous (2003) NICE to see you. *Health Service Journal* 113 (5860): 30–31.

Anonymous (2003) NICE's Visudyne appraisal coming to an end. *SCRIP World Pharmaceutical News*: 5.

Anonymous (2003) Pain features highly in public's concerns. *British Medical Journal* 326 (7379): 8.

Anonymous (2003) Should NICE be abolished? *Scrip* (2889): 5–5.

Anonymous (2003) UK NICE draft rejects Amgen's anakinra. *SCRIP World Pharmaceutical News* (2846): 6.

Anonymous (2003) Updated guidance for glitazones. *The Lancet* 362 (9385): 715.

Anonymous (2003) WHO review of NICE in the United Kingdom. *WHO Drug Information* 17 (4): 257–259.

Anonymous (2003) Winter remedies: NICE approves Tamiflu for 'at risk' groups. *Chemist Druggist*: s3.

Ashcroft D, Chapman S, Lockett J (2003) Supporting the implementation of prescribing advice in PCOs. *Pharmaceutical Journal* 267: 558–559.

Bagnall A, Jones L, Ginnelly L et al (2003) A systematic review of atypical antipsychotic drugs in schizophrenia. *Health Technology Assessment* 7 (13): 1–193.

Bailey C, Day C, Krentz A (2003) Nice timing for glitazones. *British Journal of Diabetes & Vascular Disease* 3 (5): 366–367.

Baines E (2003) NICE under attack over delay to guidance. *General Practitioner*: 22–23.

Bloor K, Freemantle N, Khadjesari K et al (2003) Impact of NICE guidance on laparoscopic surgery for inguinal hernias: analysis of interrupted time series. *British Medical Journal* 326 (7389): 578.

Boland A, Dundar Y, Bagust A et al (2003) Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. *Health Technology Assessment* 7 (15): 1–136.

Bosanquet N (2003) NICE to see you. *Health Service Journal* 113 (5860): 30–31.

Bosanquet N, Tolley K (2003) Treatment of anaemia in cancer patients: implications for supportive care in the National Health Service Cancer Plan. *Current Medical Research & Opinion* 19 (7): 643–650.

Bostock N (2003) Nice work; the firm resolve of Rawlins. *Primary Care Report* 5 (18): 22.

British Psychological Society, National Collaborating Centre for Mental Health (2003) *Schizophrenia. full national clinical guideline on core interventions in primary and secondary care*. London: Gaskell and the British Psychological Society 264p.

Brown S (2003) NICE guidance causes a nasty headache for financial planners. *Primary Care Report* 5 (4): 24–26.

Burls A, Sandercock J (2003) How to make a compelling submission to NICE: tips for sponsoring organisations. *British Medical Journal* 327 (7429): 1446–1448.

Byrne J, Garg S, Vaidya A et al (2003) Efficacy of triple combination oral hypoglycaemic therapy using rosiglitazone, metformin and sulphonylurea in lowering HbA1C. *Practical Diabetes International* 20 (2): 58–60.

Calvert N, Hind D, McWilliams R et al (2003) The effectiveness and cost-effectiveness of ultrasound locating devices for central venous access: a systematic review and economic evaluation. *Health Technology Assessment* 7 (12): 1–84.

Campbell B, Maddern G (2003) Safety and efficacy of interventional procedures: scrutinising the evidence and issuing guidelines without stifling innovation. *British Medical Journal* 326 (7385): 347–348.

Campbell K (2003) Revised advice on use of imatinib for chronic myeloid leukaemia. *Nursing Times* 99 (41): 20–21.

Campbell W (2003) Interventional procedures and NICE. *Bulleting of the Royal College of Surgeons of England* 85 (6): 210–211.

Carney S, Geddes J (2003) Electroconvulsive therapy: recent recommendations are likely to improve standards and uniformity of use. *British Medical Journal* 326: 1343–1344.

Chalmers N (2003) Ultrasound guided central venous access. NICE has taken sledgehammer to crack nut. *British Medical Journal* 326 (7391): 712.

- Chilcott J, Lloyd J, Wight J et al (2003) A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. *Health Technology Assessment* 7 (4): i1–vi72.
- Clark W, Raftery J, Song F et al (2003) Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. *Health Technology Assessment* 7 (3): 1–67.
- Cody J, Wyness L, Wallace S et al (2003) Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape for treatment of urinary stress incontinence. *Health Technology Assessment* 7 (21): i1–xii202.
- Connolly C, Bullock R (2003) Treatment of patients with Alzheimer's disease: A national survey following release of the NICE guidance. *Psychiatric Bulletin* 27 (1): 11–13.
- Da Silva P, Nguyen-Van-Tam J, Hayward A (2003) Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care. *Journal of the Royal Society of Medicine* 96 (2): 66–69.
- De Backer G, Ambrosioni E, Borch-Johnsen K et al (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *European Heart Journal* 24 (17): 1601–1610.
- Department of Health (2003) *The Interventional Procedures Programme: working with the National Institute for Clinical Excellence to promote safe clinical innovation*. HSC 2003/011. 4p.
- Devlin N, Appleby J, Parkin D (2003) Patients' views of explicit rationing: what are the implications for health service decision-making? *Journal of Health Services & Research Policy* 8 (3): 183–186.
- Devlin N, Parkin D (2003) Funding fertility: issues in the allocation and distribution of resources to assisted reproduction technologies. *Human Fertility (Cambridge, England)* 6 (2 Suppl): S2–S6.
- Devlin N, Parkin D, Gold M (2003) WHO evaluates NICE. *British Medical Journal* 327 (7423): 1061–1062.
- Devlin N, Parkin D, Gold M (2003) WHO evaluates NICE. *British Medical Journal* 327 (7423): 1061–1062.
- Dillon A (2003) The HSJ interview: Andrew Dillon. The NICE guy. Interview by Lyn Whitfield. *Health Service Journal* 113 (5853): 20–21.
- Dillon A, Gibbs T, Riley T et al (2003) The National Institute for Clinical Excellence and coverage of relenza by the NHS. *Japanese Pharmacology & Therapeutics* 31 (11): 993–1014.
- Dixon S, Coleman P, Nicholl J et al (2003) Evaluation of the impact of a technology appraisal process in England: the south and west development and evaluation committee. *Journal of Health Services & Research Policy* 8 (1): 18–24.
- Duckenfield M (2003) Learning to be NICE: Technology assessment as marketing at the National Institute for Clinical Excellence. *International Journal of Medical Marketing* 3 (2): 131–144.
- Duckenfield M (2003) Nasty or NICE? The National Institute for Clinical Excellence and technology assessment. *International Journal of Nonprofit and Voluntary Sector Marketing* 8 (2): 122–133.
- Eley C (2003) *New directions to Local Health Boards and NHS Trusts in Wales to fund implementation of NICE technology appraisal guidance*. Welsh health circular. WHC(2003)109. 4p.
- Fook L (2003) Principles of best practice in clinical audit: National Institute of Clinical Excellence. *Age and Ageing* 32 (4): 467–468.
- Gafni A, Birch S (2003) NICE methodological guidelines and decision making in the National Health Service in England and Wales. *Pharmacoeconomics* 21 (3): 149–157.
- Gainant T (2003) Where does laparoscopy fit in the treatment of inguinal hernia in 2003? *Journal de Chirurgie* 140 (3): 171–175.
- Harding S (2003) Verteporfin photodynamic therapy in the UK: implications of the NICE appraisal. *Eye* 17 (2): 119–122.
- Hargreaves S (2003) NICE guidelines address social aspect of schizophrenia. *British Medical Journal* 326 (7391): 679.
- Hayhurst K, Brown P, Lewis S (2003) Postcode prescribing for schizophrenia. *British Journal of Psychiatry* 182 (4): 281–283.
- Heller R, Edwards R, McElduff P (2003) Implementing guidelines in primary care: can population impact measures help? *BMC Public Health* 3 (1): 7.
- Hewitt-Taylor J (2003) National recommendations and guidelines. *Journal of Nursing Management* 11 (3): 158–163.

- Hill S, Garattini S, Van Loenhout J et al (2003) *Technology appraisal programme of the National Institute for Clinical Excellence: a review by WHO June–July 2003*. EUR/03/5045738. Copenhagen: World Health Organisation 51p.
- Hippisley-Cox J, Pringle M, Cater R et al (2003) The use of patient group directions for zanamivir in 2000/2001: Cross-sectional survey of primary care organisations in England. *Quality in Primary Care* 11 (2): 97–106.
- Hitchen L (2003) NICE way to eliminate pre-op tests confusion. *Hospital Doctor*: 18.
- Holmes C, Lovestone S (2003) Long-term cognitive and functional decline in late onset Alzheimer's disease: Therapeutic implications. *Age and Ageing* 32 (2): 200–204.
- Holt R (2003) NICE approves glargine. *Diabetes, Obesity & Metabolism* 5 (2): 139.
- Horan F (2003) The national joint registry for England and Wales. *Journal of Bone & Joint Surgery – British Volume* 85–B (1): 1–2.
- Hutchinson A, McIntosh A, Anderson J et al (2003) Developing primary care review criteria from evidence-based guidelines: coronary heart disease as a model. *British Journal of General Practice* 53 (494): 690–696.
- Jones A (2003) Health technology assessment agencies across Europe. *Clinical Research Focus* 14 (7): 5–11.
- Kendall H (2003) Trends in prescribing of drugs for dyspepsia. *Prescriber January 2003*: 46–48.
- Kenny C (2003) NICE guide to community infection control. *Nursing Times* 99 (25): 6–7.
- Kingsnorth A, LeBlanc K (2003) Hernias: inguinal and incisional. *Lancet* 362 (9395): 1561–1571.
- Kmietowicz Z (2003) NICE is told to break its close links with drug industry. *British Medical Journal* 327 (7416): 637.
- Kmietowicz Z (2003) NICE to start assessing diagnostic and treatment procedures. *British Medical Journal* 326 (7386): 412.
- Knott L (2003) The regulators. *Doctor*: 34–36.
- Littlejohns P, Barnett D, Longson C (2003) The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence. *Lancet Oncology* 4 (4): 242–250.
- Littlejohns P, Eccles M, Leng G (2003) Erratum: NICE Cancer Guidance: A description of the Institute's Clinical Guideline Programme. *British Journal of Cancer* 89 (11): 2163–2164.
- Littlejohns P, Eccles M, Leng G (2003) NICE cancer guidance: A description of the Institute's Clinical Guideline Programme. *British Journal of Cancer* 89 (suppl 1): S9–S11.
- Loveman E, Cave C, Green C et al (2003) The clinical and cost-effectiveness of patient education models for diabetes: a systematic review and economic evaluation. *Health Technology Assessment* 7 (22): i1–iii190.
- MacGillivray S, Cooper S, English B et al (2003) Predictors of discontinuation on clozapine: a population study. *Irish Journal of Psychological Medicine* 20 (4): 115–118.
- Maisey N, O'Brien M (2003) The treatment of non-small cell lung cancer. *CME Cancer Medicine* 2 (1): 10–18.
- Mason M, Johnson P (2003) Combination chemotherapy for advanced colorectal cancer. *British Journal of Cancer* 88 (7): 1152–1153.
- Maynard A (2003) Taking the postcode out of prescribing. *Hospital Doctor*: 24–31.
- Mayor S (2003) NICE announces guidelines for use of rituximab. *British Medical Journal* 327 (7418): 766.
- Mayor S (2003) NICE guidance clarifies when to do preoperative tests in elective surgery. *British Medical Journal* 326 (7404): 1418.
- Mayor S (2003) NICE guidance recommends fewer but earlier antenatal check ups. *British Medical Journal* 327 (7422): 1009.
- Mayor S (2003) NICE recommends greater use of CT imaging for head injuries. *British Medical Journal* 326 (7404): 1414.
- Mayor S (2003) NICE recommends new treatment for breast and bowel cancer. *British Medical Journal* 326 (7400): 1166.
- Mayor S (2003) NICE recommends photodynamic therapy for certain patients with macular degeneration. *British Medical Journal* 327 (7417): 698.
- McLellan F (2003) WHO review committee makes NICE recommendations. *The Lancet* 362 (9388): 966.
- McNally O, Delaney E, Petty R et al (2003) Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study. *British Journal of Cancer* 89 (6): 966–967.

McVie G (2003) NICE system...shame about the side-effects. *Lancet Oncology* 4 (4): 203.

Meads C, Salas C, Roberts T et al (2003) Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. *Health Technology Assessment* 7 (9): v-98.

Medler M (2003) A "NICE" pathway to successful implementation. Presented at Evidence in Practice (Bristol), 20 Oct 2003.

Meister J (2003) Quality Assurance versus Regulation – A Lawyer's Perspective. *Zeitschrift für Ärztliche Fortbildung und Qualitätssicherung* 97 (8-9): 641-646.

Mossialos E, McKee M (2003) Rationing treatment on the NHS – still a political issue. *Journal of the Royal Society of Medicine* 96 (8): 372-373.

Mowatt G, Vale L, Brazzelli M et al (2003) *Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction. Technology Assessment Review submitted to the National Institute for Clinical Excellence 2003.* University of Aberdeen: Health Services Research Unit.

Mowatt G, Vale L, Perez J et al (2003) Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. *Health Technology Assessment* 7 (2): 1-174.

National Audit Office (2003) *Hip replacements: an update.* Report by the Comptroller and Auditor General HC 956 Session 2002-2003 17 July 2003.

National Collaborating Centre for Acute Care (2003) *Head Injury: triage, assessment, investigation and early management of head injury in infants, children and adults.* London: The Royal College of Surgeons of England 248p.

National Collaborating Centre for Acute Care (2003) *Preoperative tests: the use of routine preoperative tests for elective surgery – evidence, methods & guidance.* London: The Royal College of Surgeons of England 117p.

National Collaborating Centre for Women's and Children's Health (2003) *Antenatal care: routine care for the healthy pregnant woman.* London: Royal College of Obstetricians and Gynaecologists xvi286p.

National Institute for Clinical Excellence (2003) *A guide to NICE.* London: National Institute for Clinical Excellence 29p.

National Institute for Clinical Excellence (2003) *Anakinra for rheumatoid arthritis. NICE Technology Appraisal Guidance No.72.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Annual report 2002/2003 and summary financial statement.* London: National Institute for Clinical Excellence 19p.

National Institute for Clinical Excellence (2003) *Antenatal care: routine care for the healthy pregnant woman. NICE Clinical Guideline No.6.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Balloon kyphoplasty for vertebral compression fractures. NICE Interventional Procedures Guidance No. IPG0020.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Balloon thermal endometrial ablation. NICE Interventional Procedures Guidance No. IPG0006.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Bone-anchored cystourethropepy. NICE Interventional Procedures Guidance No. IPG0018.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. NICE Clinical Guideline No.5.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Circular stapled haemorrhoidectomy. NICE Interventional Procedures Guidance No. IPG0034.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Coblation tonsillectomy. NICE Interventional Procedures Guidance No. IPG0009.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Compilation: summary of guidance issued to the NHS in England and Wales. Issue 6.* London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Compilation: summary of guidance issued to the NHS in England and Wales. Issue 7.* London: National Institute for Clinical Excellence 354p.

National Institute for Clinical Excellence (2003) *Corporate plan 2003–06 and business plan 2003–04*. London: National Institute for Clinical Excellence 41p.

National Institute for Clinical Excellence (2003) *Customised titanium implants for orofacial reconstruction*. NICE Interventional Procedures Guidance No. IPG0028. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Deep brain stimulation for Parkinson's disease*. NICE Interventional Procedures Guidance No. IPG0019. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Drug eluting stents for the prevention of restenosis (including review of coronary artery stents for ischaemic heart disease)*. NICE Technology Appraisal Guidance No.71.

National Institute for Clinical Excellence (2003) *Endoscopic laser foraminoplasty*. NICE Interventional Procedures Guidance No. IPG0031. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Endoscopic stapling of pharyngeal pouch*. NICE Interventional Procedures Guidance No. IPG0022. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Endoscopic transsphenoidal pituitary adenoma resection*. NICE Interventional Procedures Guidance No. IPG0032. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Extracorporeal shockwave lithotripsy for calcific tendonitis (tendinopathy) of the shoulder*. NICE Interventional Procedures Guidance No. IPG0021. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Extracorporeal shockwave therapy for Peyronie's disease*. NICE Interventional Procedures Guidance No. IPG0029. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Guidance on the use of liquid-based cytology for cervical screening*. NICE Technology Appraisal Guidance No.69. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Guidance on the use of continuous subcutaneous insulin infusion for diabetes*. NICE Technology Appraisal Guidance No.57. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Guidance on the use of electroconvulsive therapy*. NICE Technology Appraisal Guidance No.59. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Guidance on the use of zanamivir, oseltamivir and amantadine for the treatment of influenza*. NICE Technology Appraisal Guidance No.58. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Guidance on the use of oseltamivir and amantadine for the prophylaxis of influenza*. NICE Technology Appraisal Guidance No.67. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Guidance on the use of tension-free vaginal tape (Gynecare TVT) for stress incontinence*. NICE Technology Appraisal Guidance No.56. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Guidance on the use of patient-education models for diabetes*. NICE Technology Appraisal Guidance No.60. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Guidance on the use of photodynamic therapy for age-related macular degeneration*. NICE Technology Appraisal Guidance No.68. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer*. NICE Technology Appraisal Guidance No.62. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer*. NICE Technology Appraisal Guidance No.61. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Guidance on the use of imatinib for chronic myeloid leukaemia*. NICE Technology Appraisal Guidance No.70. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Guidance on the use of glitazones for the treatment of type 2 diabetes*. NICE Technology Appraisal Guidance No.63. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Head injury: triage, assessment, investigation and early management of head injury in infants, children and adults*. NICE Clinical Guideline No.4. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Holmium laser prostatectomy*. NICE Interventional Procedures Guidance No. IPG0017. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Human growth hormone (somatropin) in adults with growth hormone deficiency*. NICE Technology Appraisal Guidance No.64. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Infection control: prevention of healthcare-associated infection in primary and community care*. NICE Clinical Guideline No.2. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Laparo-endogastric surgery*. NICE Interventional Procedures Guidance No. IPG0025. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Laparoscopic cystectomy (of the urinary bladder)*. NICE Interventional Procedures Guidance No. IPG0026. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Laparoscopic laser myomectomy*. NICE Interventional Procedures Guidance No. IPG0023. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Laparoscopic radical hysterectomy for early stage cervical cancer*. NICE Interventional Procedures Guidance No. IPG0024. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Laparoscopic radical prostatectomy*. NICE Interventional Procedures Guidance No. IPG0016. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Laser lumbar discectomy*. NICE Interventional Procedures Guidance No. IPG0027. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids*. NICE Interventional Procedures Guidance No. IPG0030. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Microwave endometrial ablation*. NICE Interventional Procedures Guidance No. IPG0007. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Minimally invasive placement of pectus bar (the Nuss procedure)*. NICE Interventional Procedures Guidance No. IPG0003. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Multiple sclerosis: management of multiple sclerosis in primary and secondary care*. NICE Clinical Guideline No.8. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction*. NICE Technology Appraisal Guidance No.73. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Olanzapine and valproate semisodium in the treatment of acute mania associated with bipolar I disorder*. NICE Technology Appraisal Guidance No.66. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Pancreatic islet cell transplantation*. NICE Interventional Procedures Guidance No. IPG0013. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Percutaneous pancreatic necrosectomy*. NICE Interventional Procedures Guidance No. IPG0033. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Percutaneous vertebroplasty*. NICE Interventional Procedures Guidance No. IPG0012. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Preoperative testing: the use of routine preoperative tests for elective surgery*. NICE Clinical Guideline No.3. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Pressure ulcer prevention: pressure ulcer risk assessment and prevention, including the use of pressure-relieving devices (beds, mattresses and overlays) for the prevention of pressure ulcers in primary and secondary care*. NICE Clinical Guideline No.7. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Radiofrequency ablation of varicose veins*. NICE Interventional Procedures Guidance No. IPG0008. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Radiofrequency ablation of hepatocellular carcinoma. NICE Interventional Procedures Guidance* No. IPG0002. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Rituximab for aggressive non-Hodgkin's lymphoma. NICE Technology Appraisal Guidance* No.65. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Routine tests carried out before a planned surgical operation: understanding NICE guidance – information for people who are going to have a planned operation, their carers, and the public.* NO232 25k 1P Jun 03 (OAK). London: National Institute for Clinical Excellence 16p.

National Institute for Clinical Excellence (2003) *Sacral nerve stimulation for faecal incontinence. NICE Interventional Procedures Guidance* No. IPG0005. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Sacral nerve stimulation for urge incontinence and urgency-frequency. NICE Interventional Procedures Guidance* No. IPG0004. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Stentgraft placement in abdominal aortic aneurysm. NICE Interventional Procedures Guidance* No. IPG0010. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife. NICE Interventional Procedures Guidance* No. IPG0011. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Transurethral electrovaporisation of the prostate. NICE Interventional Procedures Guidance* No. IPG0014. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Transurethral radiofrequency needle ablation of the prostate. NICE Interventional Procedures Guidance* No. IPG0015. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Uterine artery embolisation for fibroids. NICE Interventional Procedures Guidance* No. IPG0001. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2003) *Welsh language scheme: prepared under the Welsh Language Act 1993.* London: National Institute for Clinical Excellence 8p.

National Institute for Clinical Excellence (2003) *Welsh language scheme: information for the public.* London: National Institute for Clinical Excellence 4p.

Newman M (2003) Is CHAI able to finish what NICE began? *Hospital Doctor*: 25–27.

O'Sullivan J, Norman A, Cook G et al (2003) Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. *BJU International* 92 (7): 685–689.

Parkinson D (2003) Pharmacological interventions to manage coronary heart disease. *Nursing Times* 99 (27): 48–49.

Parr J, Ward A, Inman S (2003) Current practice in the management of Attention Deficit Disorder with Hyperactivity (ADHD). *Child: Care health and development* 29 (3): 215–218.

Patel G, Osborne A (2003) Prescribing cyclo-oxygenase-2 selective inhibitors in secondary care: not NICE. *Pharmacy World Science* 25 (1): A7–A9.

Pellowe C, Pratt R, Harper P et al (2003) Evidence-based guidelines for preventing healthcare-associated infections in primary and community care in England. *Journal of Hospital Infection* 55 (SUPPL. 2): S2–S3.

Plummer C, Irving R, McComb J (2003) Implications of national guidance for implantable cardioverter defibrillation implantation in the United Kingdom. *Pacing & Clinical Electrophysiology* 26 (1 pt 2): 479–482.

Plummer C, McComb J (2003) An audit of the implications of implementing NICE guidance on the use of implantable cardioverter-defibrillators. *Heart (British Cardiac Society)* 89 (7): 787–788.

Procopio M (2003) NICE guidelines and maintenance ECT. *British Journal of Psychiatry* 183 (Sep): 263.

Quennell P (2003) Getting a word in edgeways? Patient group participation in the appraisal process of the National Institute for Clinical Excellence. *British Journal of Clinical Governance* 8 (1): 39–45.

Richards S, Earnshaw J (2003) Management of primary and recurrent inguinal hernia by surgeons from the South West of England. *Annals of the Royal College of Surgeons of England* 85 (6): 402–404.

Robson J (2003) What happened to evidence in NICE guidance on heart failure? *British Medical Journal* 327 (7420): 932.

- Ross P, Cunningham D (2003) Reply 2: NICE guidelines on drugs for colorectal cancer. *British Journal of Cancer* 88 (7): 1154–1155.
- Royle P, Waugh N (2003) Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system. *Health Technology Assessment* 7 (34): iii1–ix51.
- Ryan J, Piercy J (2003) NICE evaluation has data shortage and short analysis period. *British Medical Journal* 326: 1144.
- Samanta A, Samanta J, Gunn M (2003) Legal considerations of clinical guidelines: will NICE make a difference? *Journal of the Royal Society of Medicine* 96 (3): 133–138.
- Saunders M, Valle J (2003) Reply 1: Call for NICE to review urgently their guidance concerning first-line chemotherapy for metastatic colorectal cancer. *British Journal of Cancer* 88 (7): 1153–1154.
- Scott D (2003) Editorial II: It's NICE to see in the dark. *British Journal of Anaesthesia* 90 (3): 269–272.
- Sculpher M, Price M (2003) Measuring costs and consequences in economic evaluation in asthma. *Respiratory Medicine* 97 (5): 508–520.
- Shallow H (2003) Should cord pH be performed routinely after normal birth? *RCM Midwives Journal* 6 (1): 28–31.
- Shannon C (2003) Better communication is key to recruiting patients to trials. *British Medical Journal* 327 (7428): 1368.
- Shannon C (2003) Money must be made available for NICE guidance, minister says. *British Medical Journal* 327 (7428): 1368.
- Shepherd K (2003) Inhaler devices for children. *Nursing Times* 99 (11): 48–49.
- Smith J (2003) Liquid based cytology – The advantages. *Cpd Bulletin Cellular Pathology* 5 (1): 27–29.
- Stewart J (2003) Stimulated intra-uterine insemination is not a natural choice for the treatment of unexplained subfertility: Should the guidelines be changed? *Human Reproduction* 18 (5): 903–907.
- Stoykova B, Drummond M, Barbieri M et al (2003) The lag between effectiveness and cost-effectiveness evidence of new drugs: Implications for decision-making in health care. *European Journal of Health Economics* 4 (4): 313–318.
- Sudlow C, Counsell C (2003) Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. *British Medical Journal* 326 (7385): 388–392.
- Syrett K (2003) Legitimizing. *European Public Law* 9 (4): 509–532.
- Tagney J (2003) Implantable cardioverter defibrillators: developing evidence-based care. *Nursing Standard* 17 (16): 33–36.
- The National Collaborating Centre for Chronic Conditions (2003) Chronic heart failure: national clinical guideline for diagnosis and management in primary and secondary care. London: *Royal College of Physicians* 157p.
- Tiner R (2003) ABPI call for NICE guidance to be made mandatory. *Lancet Oncology* 4 (4): 203–204.
- Turner D, Wailoo A, Nicholson K et al (2003) Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. *Health Technology Assessment* 7 (35): i1–xiv285.
- Tyrrell J, Littlejohns P (2003) NICE for children? *Current Paediatrics* 13–236.
- Venn S, Edwards A (2003) Assessing the awareness of and attitude to NICE guidance within GP partnerships in one PCO in Wales: a qualitative study using focus group interviews. *Quality in Primary Care* 11 (2): 123–128.
- Wales National Assembly (2003) *National Institute of Clinical Excellence (NICE) Interventional Procedures Advisory Committee (IPAC)*. Welsh health circular. WHC(2003)58 . 5p.
- Walker A, Maynard A (2003) Managing medical workforces: from relative stability to disequilibrium in the UK NHS. *Applied Health Economics & Health Policy* 2 (1): 25–36.
- Ward S, Kaltenthaler E, Cowan J et al (2003) Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. *Health Technology Assessment* 7 (32): 1–93.
- Watts G (2003) Mr nice guy. *British Medical Journal* 327 (7423): 1070.
- White C (2003) NICE expands research and development role. *British Medical Journal* 326 (7398): 1056.
- Whitfield L (2003) The NICE guy. *Health Service Journal* 113 (5858): 20–21.

Wilcock M, Glinn J (2003) The use of Cox-2 selective inhibitors within secondary care: NICEly done? *Pharmacy in Practice* 13 (6): 198–200.

Williams A (2003) Measuring health-related quality of life: Is NICE measuring what matters to patients? *Journal of Clinical Excellence* 4 (3): 365–366.

Willimott H (2003) Does the use of selective COX-II inhibitors in the Norfolk & Norwich University Hospital follow NICE guidance? *Pharmacy World Science* 25 (1): A52–A53.

Wroblewski B, Siney P, Fleming P (2003) Wear of enhanced ultra-high molecular-weight polyethylene (Hylamer) in combination with a 22.225 mm diameter zirconia femoral head. *Journal of Bone & Joint Surgery – British Volume* 85 (3): 376–379.

Yates D (2003) The NICE head injury guidelines. *Emergency Medicine Journal*. 20 (2): 117.

2004

Anonymous (2004) New NICE guidance on myocardial perfusion scintigraphy. *British Journal of Cardiology* 11 (1).

Anonymous (2004) NICE epilepsy guidelines for children's drugs. *Chemist Druggist*: 26.

Anonymous (2004) UK NHS to offer free IVF treatment. *Pharma Marketletter*.

Beard S, Wall L, Gaffney L et al (2004) Aggressive Non-Hodgkin's Lymphoma: Economics of High-Dose Therapy. *Pharmacoeconomics* 22 (4): 207–224.

Birch S, Gafni A (2004) The 'NICE' approach to technology assessment: an economics perspective. *Health Care Management Science* 7 (1): 35–41.

Boogaerts MA (2004) Oral fludarabine therapy in chronic lymphocytic leukemia – increased convenience. *Hematology Journal* 5 (Suppl 1): S31–S37.

Brennan A, Bansback N, Reynolds A et al (2004) Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. *Rheumatology* 43 (1): 62–72.

Centre for Health Services Research – University of Newcastle upon Tyne, Medicines Evaluation Group – Centre for Health Economics University of York (2004) *Prophylaxis for patients who have experienced a myocardial infarction: drug treatment, cardiac rehabilitation and dietary manipulation*. 115p.

Czoski-Murray C, Warren E, Chilcott J et al (2004) Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. *Health Technology Assessment* 8 (13): 103.

Duerden M, Gogna N, Godman B et al (2004) Current national initiatives and policies to control drug costs in Europe: UK perspective. *Journal of Ambulatory Care Management* 27 (2): 132–138.

Foot B, Foy R, Chakravarthy U et al (2004) Increasing use of a new health technology during the wait for NICE guidance: findings from the third national tracker survey of photodynamic therapy. *Journal of Public Health Medicine* 26 (1): 52–55.

Garside R, Stein K, Wyatt K et al (2004) The effectiveness and cost-effectiveness of microwave and thermal balloon endometrial ablation for heavy menstrual bleeding: a systematic review and economic modelling. *Health Technology Assessment* 8 (3): i1–iii155.

Gerhardsen T (2004) Making healthcare work. *Scrip* (130): 26–27.

Hewitt-Taylor J (2004) Clinical guidelines and care protocols. *Intensive & Critical Care Nursing* 20 (1): 45–52.

Jones L, Hawkins N, Westwood M et al (2004) Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda(R)) for locally advanced and/or metastatic breast cancer. *Health Technology Assessment* 8 (5): 1–156.

Kelly M, Newstead L (2004) Family Intervention in routine practice: it is possible! *Journal of Psychiatric & Mental Health Nursing* 11 (1): 64–72.

Kirby M (2004) NICE – Glitazones. *British Journal of Diabetes & Vascular Disease* 4 (1): 57.

Klien R (2004) Britain's national health service revisited. *New England Journal of Medicine* 350 (9): 937–942.

Kmietowicz Z (2004) Palliative care services should have higher priority, says NICE. *British Medical Journal* 328 (7442): 725.

McInnes E (2004) The use of pressure-relieving devices (beds, mattresses and overlays) for the prevention of pressure ulcers in primary and secondary care. *Journal of Tissue Viability* 14 (1): 4–6.

Meads C, Hyde C (2004) Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review. *British Journal of Ophthalmology* 88 (2): 212–217.

National Collaborating Centre for Chronic Conditions (2004) Chronic Obstructive Pulmonary Disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. *Thorax* 59 (Supp 1):1–232.

National Collaborating Centre for Mental Health (2004) *Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders*. London: The British Psychological Society and Gaskell 264p.

National Collaborating Centre for Women's and Children's Health (2004) *Fertility: assessment and treatment for people with fertility problems*. London: Royal College of Obstetricians and Gynaecologists xvii216p.

National Institute for Clinical Excellence (2004) *Chronic obstructive pulmonary disease (COPD): management of chronic obstructive pulmonary disease in primary and secondary care*. NICE Clinical Guideline No.12.

National Institute for Clinical Excellence (2004) *Cyanoacrylate instillation for occlusion of parotid sinuses*. NICE Interventional Procedures Guidance No. IPG0042.

National Institute for Clinical Excellence (2004) *Eating disorders: Core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders*. NICE Clinical Guideline No.9. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2004) *Extracorporeal membrane oxygenation in adults*. NICE Interventional Procedures Guidance No. IPG0039.

National Institute for Clinical Excellence (2004) *Extracorporeal albumin dialysis for acute-on-chronic liver failure*. NICE Interventional Procedures Guidance No. IPG0045.

National Institute for Clinical Excellence (2004) *Extracorporeal membrane oxygenation in children aged over one month*. NICE Interventional Procedures Guidance No. IPG0038.

National Institute for Clinical Excellence (2004) *Fertility: assessment and treatment for people with fertility problems*. NICE Clinical Guideline No.11.

National Institute for Clinical Excellence (2004) *Guidance for patient/carer groups*. No 3. London: National Institute for Clinical Excellence iv31p.

National Institute for Clinical Excellence (2004) *Guideline Development methods – Information for National Collaborating Centres and Guideline Developers*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2004) *Hysteroscopic sterilisation by tubal cannulation and placement of intrafallopian implant*. NICE Interventional Procedures Guidance No. IPG0044. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2004) *Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C*. NICE Technology Appraisal Guidance No.75. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2004) *Needle fasciotomy for Dupuytren's contracture. NICE Interventional Procedures Guidance* No. IPG0043. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2004) *Non-surgical reduction of myocardial septum. NICE Interventional Procedures Guidance* No. IPG0040. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2004) *Off-pump coronary artery bypass. NICE Interventional Procedures Guidance* No. IPG0035. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2004) *Partial left ventriculectomy. NICE Interventional Procedures Guidance* No. IPG0041. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2004) *Pre-hospital initiation of fluid replacement therapy in trauma. NICE Technology Appraisal Guidance* No.74. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2004) *Radiofrequency volumetric tissue reduction of turbinate hypertrophy. NICE Interventional Procedures Guidance* No. IPG0036. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2004) *The Guideline Development Process – An overview for stakeholders, the public and the NHS*. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2004) *Transilluminated powered phlebectomy for varicose veins. NICE Interventional Procedures Guidance* No. IPG0037. London: National Institute for Clinical Excellence.

National Institute for Clinical Excellence (2004) *Type 2 diabetes: Prevention and management of foot problems. NICE Clinical Guideline* No.10. London: National Institute for Clinical Excellence.

Penn E, Rayment S (2004) Management of a dehiscid abdominal wound with VAC therapy. *British Journal of Nursing* 13 (4): 194–201.

Rawlins, M, Littlejohns, P (editors) (2004) *Delivering quality in the NHS*. Oxford: Radcliffe Medical Press.

Roux O, Lacour J (2004) Eruptive lingual papillitis with household transmission: A prospective clinical study. *British Journal of Dermatology* 150 (2): 299–303.

Ryan M (2004) Discrete choice experiments in health care: NICE should consider using them for patient centred evaluations of technologies. *British Medical Journal* 328 (7436): 360–362.

Song S, Brown P (2004) Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. *Diabetic Medicine* 21 (3): 238–245.

The National Collaborating Centre for Chronic Conditions (2004) *Multiple sclerosis: national clinical guideline for diagnosis and management in primary and secondary care*. London: Royal College of Physicians 213p.

Turner-Stokes L, Wade D (2004) Rehabilitation following acquired brain injury: concise guidance. *Clinical Medicine* 4 (1): 61–65.

Underwood S, Anagnostopoulos C, Cerqueira M et al (2004) Myocardial perfusion scintigraphy: The evidence – A consensus conference organised by the British Cardiac Society, the British Nuclear Cardiology Society and the British Nuclear Medicine Society, endorsed by the Royal College of Physicians of London and the Royal College of Radiologists. *European Journal of Nuclear Medicine & Molecular Imaging* 31 (2): 261–291.

Usher D, Dumskyj M, Himaga M et al (2004) Automated detection of diabetic retinopathy in digital retinal images: a tool for diabetic retinopathy screening. *Diabetic Medicine* 21 (1): 84–90.

Wailoo A, Roberts J, Brazier J et al (2004) Efficiency, equity, and NICE clinical guidelines. *British Medical Journal* 328 (7439): 536–537.

Walley T (2004) Neuropsychotherapeutics in the UK : What Has Been the Impact of NICE on Prescribing? *CNS Drugs* 18 (1): 1–12.

Wanless D, Jones N, Anderson R et al (2004) *Securing good health for the whole population*. London: Stationary Office 214p.

Wathen B, Dean T (2004) An evaluation of the impact of NICE guidance on GP prescribing. *British Journal of General Practice* 54 (499): 103–107.

Whitfield G, Williams C (2004) If the evidence is so good – Why doesn't anyone use them? A national survey of the use of computerized cognitive behaviour therapy. *Behavioural & Cognitive Psychotherapy* 32 (1): 57–65.



*National Institute for
Clinical Excellence*

*National Institute for
Clinical Excellence*

MidCity Place
71 High Holborn
London
WC1V 6NA

www.nice.org.uk